var title_f5_35_5680="Adaptive servo-ventilation";
var content_f5_35_5680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F84026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F84026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Principles of operation of adaptive servo-ventilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Principles of operation of servo-ventilation are depicted.",
"    <br/>",
"    The airflow tracing (top) depicts a classical crescendo (orange arrow) and decrescendo (red arrow) pattern of Cheyne-Stokes breathing, followed by an ensuing central apnea. The servo-controlled automatic adjustment of the inspiratory positive airway pressure (IPAP) level is inversely related to the changes in peak flow levels over a moving time window (bottom). Specifically, during the crescendo pattern of peak flow rates (orange arrow), the pressure assist (or IPAP) level decreases in order to dampen the rise in inspiratory peak flow rate (or tidal volume). Conversely, during the decrescendo pattern of peak flow rates (red arrow), the pressure assist (or IPAP) level increases in order to dampen the fall in inspiratory peak flow rate (or tidal volume). Therefore, the servo system dampens the inherent oscillatory behavior of the patient's breathing pattern and smoothes respiration. During a central apnea, the device's back-up rate becomes active and ventilates the patient (bottom).",
"    <br/>",
"    The IPAP level is depicted in centimeters of H",
"    <sub>",
"     2",
"    </sub>",
"    O with a maximum IPAP (IPAPmax) set at 17 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and a minimum IPAP (IPAPmin) set at 9 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O (horizontal interrupted blue lines). The expiratory positive airway pressure (EPAP) level was set at 7 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. The pressure assist or pressure support level is equal to the IPAP minus EPAP level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Antonescu-Turcu A, Parthasarathy S. CPAP and bi-level PAP therapy: new and established roles. Respir Care 2010; 55:1216. Copyright &copy; 2010 American Association for Respiratory Care. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5680=[""].join("\n");
var outline_f5_35_5680=null;
var title_f5_35_5681="Eosinophilic fasciitis thigh";
var content_f5_35_5681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDbhmK4DE7c9qt+YroSuCemDVDBBBGCpqRZNxUMBn1Arz7H0xaBCJ0x3qcttUFc5z2qou5cq+CBzUiszZwvOMD2oBGlFcLsZW4HvRHI7RnzFA54IPWqduSq8sGPvVyJwyjd0pWLQtuAH3ZIPX6VJI+CWZh9O9QPHjcVbjPftUYJjBLgnceBQVuXYJl5JOFpyjYwYD5TnPYmq6HdKBswMd6sPGpQANtI6Y5pDQpmJbbhskZ56UGcAA5I7dKZI+4YOMY6nrUasIx877+eBSGWo2jLlVdd45znBps5yqpkHB696jKxq+/2/SrASF1DE7cD6E0wEzIMYYt2PaowJWPIBPqKsAByCGyR14pisRMyhccZBoAlghYNnO3tiriCOSNZFPAOOB+lUYSOFLsfQD+daZZAiDseMioYmQN5atjAYZ/WmS53cp97g8cVI42yEquVHUd6juppFYBUznBzjpSuMkRl2bRxjsarSsHbaxxjn0obzAMop5OcGq8qF5dp6dTk0XJGEo5Aj+Yq3AHHNXNq4G7IPf8AwqDACbwnyjjpzTElGSWbIPb0oQ9S3ERsYgcL0FEcnmnkcMO4prSBFOOnTNMjUhfMzjHOKCeYlUYJydzH2xT5LhIVCyHBYcf4VRMxmlyrfIh7UkkcDyJJI5yhz16mpZV+5oJInLEbnPQ0BkYFT6Yx0pFERxJjcB0xSKEQM33SeuaEK407kUImOvPtTiA7qqDJPSmREMN2SCD1P86uRyRJlhjIouTcrpagTs0rc+g7VaKq2R95h0FQm4hiO58lm5qO4uUjQlThj3NO427jLkyA7U2KuefehYzgDOMcnHr6VGWEjb2J6cBe1XY4iYASuCecUhakDBSoA59SOn0qe0hRGwF3c8knpRHb7ASSR6ZqfBijcxDJPU+tFwK9xsViiAZPfuagmCqoydpxg07JSPdJhm7k1n3EnmTKuTgenc00DBkcN8pYj1FFShgc7VLc9c4opi1OUAZgN2AAfTrQhCnJGcdPeod+xdhywzj6UjsCpEbHP61utSS0gWVgwyCO1WUiVQCjEjOT61nwS84JYEc5NX458kqSCKGguMBXcX3Zxxmp4pP3eCw56ZPSoBtyMbdmeRQHTc2fuhun9aT1GWmJG1iw3U5MyDJyST1x0qurbn3buADxVqF/MO3eAuPSky0x4fBKnOe9Sq20KGT5cUqbgeSpx3NRqu9+Dz6HvSKTFuTnoNoHIFRoZGnC7MDpkn9amkiBZCz8j9aasiJJ97JGc5pDJ4I1yWPzuOhp0imYHcpQLyTTFliwWRgMddpzT0kURkBi24Z+agRJErkqwkByOaekrCZVVGZWyCxHAwO9QGcx4YtgD2p9w+EJJIHU4pXGTmRIm+5g4xkDtV5ZcKmEJ461lRSAjuc8jNWI5HYjaSE6ZNS2SySeU+bhMEHqM/rUXmuhC9e3FOl3bwyqrHocinxltwyuMHqKkYpRjGp3Nkc9KgFs0rc529yeSKuRFWBG7JHalXDuwZSF7UXBFNopFcKCWHYmlS2LElcYOSB71aaUbtgycD71EUKx5JJLN3p3AoTkw7UQlnPJyMiq5uB0YhgeMVfmKvKBEDkD5ie1QRQRtP06D8qYrJlVQysW8sFe2P6VJIVVkVo+CPyq6WMmV2DcP1FVbg72Ee7DDlhQA9JnAKoo2nlie1RySs8nXKjk06GEg+WA2T1JPFXIoVhA+XJxkgDNIViKBwwJjVmGeMnpT2kVQQPnJ7e9NNwkdx5IzuxkKBgClCIMkDb24pBYiZfMAYjB9ar3UZdV3lm2tkKO9aQgQ/O5OB0HY0rKJSu1MJ1HHJppjRHbQsEVnUIe4q155Zgm3CY6+n40NCsalpG3H07CmOzEYxgnpSBks2CuScj9aY1ypHlRkblHzZ7VUfeiFQeSeuelRB2jXaAWY9W60JCsF1KzAIi5BIy2aqKgRvvEt9amPmn+HLNzilUBdu/mTHTFWmkIcqsB94DPPNFRuRK25lGelFA7HFqzAEn7o4p6KW5GDz09qSNhsBC5ye3epIwEwRhAPStttjJMk8kbD5W7cD0qUwgKC4C7h0pwkIwcHkdB0pJHDBS+QyjuOlK5QRbUXbtI9xSyNn5FwxHPNATjKk49DzmkdCwPI9cjmnoMlQlRzgDqSKtRFQCSev4VRjd9qoh38nn1qVJCCEIBGe3ak9wuX1DCMkHPPPPSp4SMqCuSemO1U0UBsckEdc1YX5m2gEEd88Vm2O46dTI4ypbB5Ipqp82CMZ9RUkasE6nPoaVTsYOSXB4xQXcrhRC2zbhmO7jpT5Jdg3LgjGKfLDG7ZwAw6EHkU11EkYUHPbPrT8guMil3/LICRmrZYNGIhgAcAZ5FVVLIxxHtz3pEJ8z5sZHNFgsOGAhLA78kcHtV60fdCcKetUZHEj7CCCOM1PbyuoCxkYHc+tS0M0UCyIhwy+x6mlUsXKKML656Cq7S7tu889eB3pwlfdhQdvrU2GkWIyBkLgY6HHPNLsdQDvyeoFQoZUH7wjDd+9Oj8yQkK4xnk+lCDYUSIqEs24njPpUPnNIx2ksoNPngEcRVmLFvujNRpiIBCoRf5mnawgh35ky/U5wRggelSRxK6EAgkHOQelClFYHpu6D1p5KRfw/KeeDRYFoOKksSfuqOMVGIo43aUjzG9KaZDLkqeBx160+B9zsNpAH6UwJ4JBECZQpLdF9qV5tr/dJVsdB39KhjbdIHEZJ6ZPYVbjQs7E8DHWpYmiuVDlgVw3qBSGMKQoBYDk5NWCArnB9sVWwWlKLnH94HpTsJjUm3grGoO3j2H0q5BlUJYjAPFU449zMEJAzg9j9aluHaMLGgBfPJ9aQlqShhJk/dQDvVdp1y235iBwT2qN3JUIzckE461VmkzhMkDtjiiwyYOoiKrkse5HSljXYMnl2HJFVmYlBtyOcDHWp1zFCoBBbtk0CsKtwMsXUgDjB71FsYPJI/pwM9KJAdueGbvUcrBoyu/OO9AmhiyED5TweaKg8xI/lJXNFaIRyoygBjO1+4qVSA3XAI5XOeaZB85yNpx2/xozuPcMPXtWhgmW4iAufmHripzKP4V3VRV2UlWPbof5VYTIY9No4PtSNESFWJDI+BnpQrfNtOQT6U1Udt+xse3anJGytibO49O4plD/JdSDFgjrgGljXDlnUBj6VKu7YcbWJPbgUKoTczLnPOCen0qQGpN8xV2AOefar0c5VMcZ6DFZcim4ZZCioQeQe9WvLztZW245qbFJFtHLOpz8o9D0pJZwWwrZx1FVpMRorcrn9TUgQMC/CkjGf6U7F2Jo33SMd5wevtU33uQTtHUiq8MT7unIHHvUzh1VSrKAOpJ4pARMwVvmJOTgd8VYEajJUKT1wOtNVMgv39u9TwwiNjJuYnvQxg9uZQSW2nrnpUSwER5TJ+nU1eG+Yncnyj1qUxhYwEGM9Oai7sCZVhRVUgvksOM9qesLI4LyZ9qbvKEhgpPoO1OW5D5O3BU4obHqPnQ4Us2cdBUttGQ+M44zUZ2SKewzwc1HGztvLN8nQetSBdmCEBi/bHFUZ5kOAVBPVc0srbYzzx6VVjBnkwq4xyTTQi3GzGQYXPfmiaRmcCNPMJ7dvxo3vGqqq/L3YelIwYj5XCk84FNgSxwtgLEVAJ+bNXdqJGEAGT7VCicKd21R196tSMoTABPsOtTcRECFkHXaMfjU3zFt3AT1qpIHkmAyQo6ipo0c85HljoPSgGLKm5ZNnD44PpVco0MSru/eNgswqSdnVWbfjaMnAzmoNxdRxlf9rrTV2gLqIIl8w5LBe1VpbgADPGKdHIdzKScY6iqgi8yQsQdoOeaDMFIZSY168fhVSTGQGBb1JqeaSNWPzcr2FZ5m86Y4BCKc59apDUi20mR0O0DPHU01TvYOWz7CmquULDhTwO9Dr+6UZyRxyMZqR3Hg5GBjaeOlU5IwCzMxAzgAVI5Kx7nGSeMZ61FuByQN5PRapaCGkID8y5PfIoqNmYnov40VYWZzUeMDhuepq0ed3yk554qpCpKKd3T8qmTzIgNjH6Cq3OZC5w+45PcAjpVmOVMBj8p/uk1UYcgscZ449akRF3EMAR9aLWLV0Xll+U5IAPJqwspb5CMHg5rODcZbHHApTPiPCglhzhep/OlYo0F4xhhjqajfzMB49rc859P8ajSZC6r/F2qZXYZUjjrmgpETFo8uFDZ6huams2yuFbk9STUzKpQMF+Yeh71WC+UxCgeuc0XNLothgFZWw+O1SI6PCGwFI9ahgBlXqBnqT6VLGxQYYhlzjFS2G+xYg5Xa7YcjsakJVQqLtLe/eo1KtySDjpio97SYYcMOhNJDJoo2LZnGFB4x3qymxyGRCQMnk1TimYACUEk+lXBuB+VcAjrTYFiB9x64GMEH+dE2DGVXIycg5pF2BVGwgjoc1WllZH2gDYTyetZtAtyaKMhSzKD6ikRZGJYjag4xjrUcbO0eVyfVfepg8/l4KhQR0NBQFE25UsxA4FQSyMdq4OwDnFOOF+bJyDjmooY5H3M2c9APWmBEimVhlmbJ5Jq5bFlOCgUEE59KdDbeRsLMCcdM9KSWXyxjywz9B6EVIEczsSIwN56kf/AF6ntXB+YqVPv1qjktNvJIDcZ9KdCswuS5kDRkcDoap6IVjRjfAJb5VJ/OrBm2RgKOAOWHaqLOWIXGFU9fWpPPjfeHPHepsJjwXlkAjztzy1XIl2biTyfTpVOKQFsRgbBwMdquHyioVuSTQwKdzGZ0aNJCMkbiOn0piROGO9xt/u4xU7DazBBwDnJPWqzSoz/KxaQmhN2sO4/PzFc/M3qe1Mnm+XauMAc4pHGDuYdBzgVBIQdo6Ac4FVYlorzhY42dx17dzSW5VY13AMSe3OB9KhvxPdGLyZhCgYF2I5I9K1IZo4ewJI+ZsYoIaIHkZR8ijgck1XneR36jHtT5BmUmQNyegquZVbJ4CKaaQrjppBuG7CLjnikDHyt+CEOQPWoJiPM+WIsWI35PAFTAxqpU4ZVOPrQA1QpUFdpB7+tFRsWc5STavQACinzDOWtnDquSVHrV6NN3QYGfzrHt5AvA6dv8KvQuwUbASpPftWrVjmTLbKTnoR6+lSxA8KR09e5qIz8DaMcc4qRpVxn06gVNzRMl8vdkYDemDUTQYfBPPY4qTKuNwAzjrnFSKEd2G5unSkWMCfKpAG5SOfX6VIzB5AWyDwOeKaT8rLnr70xAjIcg57c0DReRTuAAz60rwGXa4YKw64qrG5UBwCQO2cVb3qQrB2yPUUWGh1uI1kKHqB1xTjhPu87h9c0eaFkDALgjqO9KGKhiVXH8JB70i0SQyBVCoOVxkH0pxi81sxOE571Eki4Ziqk9BjpUiEmMNyi9RQDdiaWNxnaUZu6jirG0iNAVIJ71VVo8BiwyOM4qyspCYOGXp6UmFwAY5DMMDrUbQM8gZHAI/hp5wyjIKr71BcOnVCwPSp3LRNCTE2Gb5v4s9Kshg65L7iOMVRt5EOC7Yx1z/OpRIzMTlVXPahq42OuCu7G4AjqKjhn2ygsSSOfbFQSOHbAb5h3p0Z2Y3Zdzxn0pk3Lcn7w7nOxTxUNzO3lgRkbiMAntT/ACeVLAnAyO9RmAkkjgDipAjiXaq+YSSfT1qR32c5PA4A7mjjahCjaPU96aImZSwByTgfSnuFySPzHG5i3PGKnKqsajjB65qKA7XUEbnUdasvtyjOpyOgqWIbGpjOdme496sJcYj3kMCe1V5ZSZFJBUUrSA/Mo3E+ooBiXMjyjAG0dfxqOFAibUGSeopys6v84/TpS7towrDI5PHSmn0HsNuNwX8smqruRgAZIPGKWWQsu3BJJJ9qYse3aMEt7dqaFclKhYQMEg/jil835cKuVHcilZFwMn5h/DmoCzFsYyvf39qZArMC2454Hze9RMpdcKBg9KeGRsqwB45HbNKgAkHTL8DJ6D6Urk2IUVI8LnLA880yQn5sDbznmpJZI0kcKRuHX0qsp84sXUiNeBn1qlrqTccyO2CjKvqCM0VA+CcsVB9zRQFmcPFIePfnPer8ExCZBO30rNjIwCT+Jq1BuX7rEc/pXSzlia8JDL8w/Kpcb8nIKnoDVVPnTAPXpiprY4GHHJ4I7GsmbRLkexVwSNwXp0qZXDAbSQQMYNV1yc+WPqMf1qRE4yfukc47Uty7kdwMPzwT2FOGW6kH0BqFhILnl9y9KeoKSMF69Qe1JlDmZgNoXv1qwrlYhgFmHJzxUD7gjM4UHPOD/SnRncTjKnIyOxouUmWyHYhvlK5wc8Ypxf7u1AFPXBqu+dox82TjHSpVYBSo6dB60FIEO1wACBnp/WrgdZYAATgZH41FAj53FuB6ilYbHPz4+lIdx4KsuwoQAOhpySEIpG5cEjn0pp3YySCuOo60xUct8zFl64FIe5bkkLLsK7u4J71AVZguQOc8elTfw8gjAycUSBWiPOCO5pCTsQIr7yCilQOMf1pXcqjZTBxxiomLR5VtzHPGDSmbcwULg9OKWpXMP3MduAc+gFWIJwi7ivzdBmqhU5HLEH0qwsb4wBx7npTYXNBrl3UIu0E9SOajyxyhGU6Z6VXiKjAwAenHSnQo2T85Ydc0hWsKADKOwQ46VF9t3Xi25XbjvnAqeMGSU8hVHHFDojOpYDIP50mBZj+RuQpPTjrT5pExlxg9Kro6qc9GPQY60gznfJjPpSEKDuO/jC9CxxUqE5JIyPalJCx5ZQFPalWQFSGB45C+1AxJDjJboegFVLyRxbbkAxzk9D7fWpLl5DEWA24PGe9Ry4kiHB5GNvpQkK5EjBYkdzngY96my5X5FB9qjWM7VLgYAwFAp0gwmxSAe+PSqFdCSKqbSWJIOc9Oah5GWcnLdAOKap2vt++SOuOKa6MZgCceo96aQmywpjXavU4yMVXaZWd5Ocr69vpS7tsmON2OD6VHIVjUqvzFuvbn3NFiSF5kEirI0ayOpcL3wDyf1p6/6obskE4AqZ0icIWQYXJzjnntTZdn2cBVyAeMjmi4kiIx7jnj8aKdwQD8xoouxnne4qA3UirVvJlsE4NVkyNyn65p0XDlc8+tdclbQ4IO6NiF9vy8E1PBNtJBAIPNZyn36c1bhKkgnn61k0bI0YX3EbOlWYuWOWB9RVBJArYPB7Gr0LKynHUVJomMdD8zDPPT3ptsCzkuvI4B9KnKgk4Y88ke9QElX+YYOPwNI0Q6YnzfmRAx6Ed6VDknIJUDHHWmM6lzgZx0x2qIO5O0scckHFFhliKNGbcrHPcetWYiyuhIz29zVa3dgM5G3PGPSpvMbzBwDGeOKRSLquOXIOKU4kXKk7vRqRSRlQOnByOlDp5iAs5HfgdKGUVxIm7L8AdKeZxksCwx3FLPAMLuTfnvVaRSu3YWVge3IpJjLRutoCqCCeQcfpUglO0IoOexqO3idpWEmCpxtwKstEQSd2BjpSuugWI1jdgM4B9R1oktllOFYr244P1qeIKyb0AI9QajnEySbl2+/PalcVyxEqQRAEDKjA70pk2j5gDntioVcgElc5596Z5juOGAXvjkj2oFcmn2LHtyMn0qKKQIBtJHrSRBZF3NwAeg65p5VF5bLDv2oG30GpKEUbNxLnqf50SsPOwJMr2YDk1CZgzbo0fLHgH0HfFWfkWI7l6d/egm5NFKmQuM/wC16U9G+flcsT1IquiknIABHepQWBOx+nakBZWRmyAGJHQnt7VENzEuzbUHXA5NNLZYAZY98UxdqysM7ievPSgBs8pkLEjYidz/ADqUKQuFIYnqTQseWDFjsXnAPWh3wSCPmIPHai9wsR3EzKQuOemSOlQxgliz8qTg88UshOFXPHTJFJvwhAwR0wO/1piJFQIjbCNze1NVWKlARx1/xqa3QMSgIOB8x64pZ2by8Rbdg4zihitcrTKvlkyrheg9TVWJ1Qgk71z6dauSvGsak5LnOD1/GqknVQeo6EfzppjJHwxUZBxzgVE8gLkHknpjt701fvtIpJYDAHT8aaWDhm3KR0OO5oSEOafBwowPcdaKkhhXyl38nHXOKKrQRwE8ZDbh0P8AOmxAr9R61ZC7lxjiqrZDkH6V6uLo8suZbM8TBVuaPK90WoyScj1xirKNt6HBz3qrGQOvQ1Y+YkA4I9a4Wj0osuK2VIxz1watRTIigMME8fSs+IluAMsOhNTsWyqnhTWdjRGum3ygc7WAxQCsincuOOuc1UimZUCFgV45FSvIFjbDY7gikUmJHFk7lwV/WmzKo4O7DdVxz9aVc7AVbg9e1GWyP0J7UikxqITJvRjgdV7GrMeA2QCM+tRwjym+U9T6dalHqOnT1pFl9AAoYn3471I7bogARhfTrioLMq0YRl5FOlkDMdhx2INS7jQwXIYMFzxx9KjmkRozu6twccVIVVtpIBHXjvUBtFz8wYrnKgnNPQY6yuJCuH4bpWjGWXG9hjpzVB1jQEB/L7804zlMEsD35pPULl9JEIAUgIO2KhkdZXySwAyMj1qgblWXywCpJzxUkKjjIHrmkSXPkxncQRURkTO1Ccng44oVF3sFJ55OetKYwr7eNp4JoHqLv3TCOJM+rAcCnsHb5eeDgn1q1BbhQMAquOpNSOAVVSR+FFwsVY0APsDkcVGBmQhEJb17VeWMsFUYCjp2NOKhWXA6daVxlXYCuQ2Gz0HSlYAZ2Dr1Ipcl3ZSAF7n1pSQhBRTtz19aQBgjkKQR39aeMbM7Tz2FCySMc4CjtzUbyhQxcryM5HagQ55idq8be9MkYybgeh79MfSoY5ExvySx6E9Kc27bmMjeT1PpTQr3Dy8/MQdozgU5Vz8u0Rkngjk0+JSoGece3FEw2oz55IxnpimANtUmONTjviic/Mq9PX3pq5kjVEbH941DcuFXaGA4xntRYBs0gdyG4VfSoFw77zhVA+7mpDH+6G0kY5571EVGQAOSfmPamtBEUSl1IQBVY8t0zUyhRhSuBngY605jnlRgKMDjiq63CuW2klhwT6+1FwLLjcxIxjt8xFFVHlbd8sXA9aKdkByaNz3BPeqt7uRw46HtirY+7nj6etRXS70Ye2QfSvpMRDng0fJYafJUTGQsCgwcEetTRPzggjHXPpWdESqllPTqKthgwUjJ/nXis+gjc1rbaTkcDp9KukL5Iyc45zWGkpjkyScZ61f8/K5OCPWspKxqmW1QqRhuoJzjoadJGyxglx+A71Esm4qUIOKsO+5MDnHWoLSGxSSY56fTpSOR5iyJnJG046Yoc4wNp24696h4Lck5x2oKLkbFRnqvb61KjjG5iRjpUFvKAuxiCB3xUh3FQVCsO/vSaGmWYpRsLYJGetRNc+bhXVh1APrUihPlwpHHFRy4Z8kNj0xUloFEnTBC54Oe1Tq7Pjaxx05HWqzOgJRGcYAyW9fb2qVJWC8HOT3oBskdX3ZfaVIx/wDWqJwiOpZjj060+WVRkYK5x15qIYbncPr60xbj/MKsM/dHtzj61OlzExyo49AOlU1iIk5bCnn1zVyzwjAKhx3JpFJFlHjXbmPkHgetSO/mNjsOwpsjJn7uS36VIiAR5Vuey5pFFlQV2hyWH6UkmACqKCT37VAJXC43Zx3HapFUgYBIBpCFhbO7cSR2x0pysxG1iAT27UgkwFSNTk9TQsQLDcMH2oGRzJsQbmBc/wB2ow8m4DPb9KnlkCRgKFLE8ZquY5AQFcnd1PpSFcYjl5HGDnPelHyMSwwMc+5pyKqsVDMTnkk0rFW+UEHH8XpTJY1ecD/Vj0I61GxbcVjGEHVqSecF8I3yjq1IvzOBG3y9yaYItb9saseV7Ad6jmcvGQV27jwKU7wp5AA6d6hZ3OAqk560ASiRANisCSOlQKCzs8oAQDj0Ap4jZRuXAjzjnqaLiNZSC25gDnaDQA9EZkJUjkZBHQCq5Vk7hmzxjuakUlNu75B6d6ZxEQpzuc5Ue3cmgQ2TdhPMPTlsdz6CmfwNtVd47dgKVmYBlQDcT949AKiLkkRlflx0Hf607ARcADc6qSM0VJ5G7nCgdgaKdmK5yoweADn0owWABoB6HBz2pzYRsc4719Uz41Gbt8uRlwCP51YiUNjyzj0pl6pXEpH+ycdqWBskAcHrxXiYinyTaPfwtXngmydUBYnsetO/eLxnoe/pToRucgEFj0HtVqRQFB4J6ZrlbOxEVq5V/lzg1dkYgLtP1xVVV5+8BU7LuZAO3JGallrQslyQofHqfSoUYFiRxjt/9anFCxypAHX8KDGU5AJ+vakUtQQY7ck5+lXYGAC5PB71T5ycjpwKfG7YIPy4656igLNF7f8ANg5BHf1pzyHZt4HoaqRM4zkFh6GpI3BYgoVOcDPSpZSF27gNxwaiYMrqiZZuuM9/SnTOSvII9eMZqGNHYBlOAB96puOxMhZhhzgH+HPerECNtGNvP6Uy2h3k5Ukj9K1LWLHO3A9KB2KkIcsCQMirwXaVbAbdye1TG3DZGdgJxkdaQKB8oBZumSKCri5UAFiB9BTYyvlkRr948mnNFggKcHvk9qT5QDhh7UhAiFl+UfmO1SEgEKTjNRIzZIZyFPGR1NWlCIoP8A9euaTBCmRYwpKls8cCo3inkZShWNA2WJ7juPrVkESqpU89QKR2ESkS/N3wOhNMdinOIowOdw9jUW453HJ44HTFNubhTuCcZPryKrI7M5DH5Rzz3oETs6A7AuM9QagC5ZmDcdBjsKnSF3xwFZuSfSrSWxQBowM9AG70IRDDbjYowUZhnkc1PFBGqksoCA9fU1MkTLEHmK4B6HvTs+YmQuCTwDyBSbHYgkRZMBeg7dP0qElETkAYOOKlmcR8rySeWFQOFcAN1HJpoLBMEaMMVyRwuT3pDE6IDHtVjyQegp6pmQDII6qn9aGbG4qVZs/gKBFO6O98fMT246/WgKV278At1z29qCJlMjyBRIecegpZWLQjK5Y88d6YgniaOBX3DL4A/wD1VUYkMvJJJ4p800siASZ56AUgVkIAOeMBSOn1qvQTGtHuPy+YwHGV6UU4Ond9p9BRRcVzkgBnPNOPOD1J70insfxoYf3T7V9WfGjJ1Vw6nOCOBVKJ8H9DzV5upGeRWfOm2YgHGeRXDjad0pnoYCpaTiaFtIDhuPSrIfgEHHpjvWVbyEDkAkVcikJVfL5PpXkSR7cWakCoygk4PpTGTbIHHPPb+tMhkAy/rxj0NXIfmGc5b0qDRMcANo6gjr3qxCAw4xn0NV5PM3KOgx0pI5NpIQ49RSD0LnkKjklCc1I8KYzgHH60lvLu+VvTp61NJnapUAeopWKTKvEZB2/KO9OOdoPGT+FSTfIuGzge1McBgTu7elSykVy3zMMn0GafAoEgUn7vYmmMrEn5gO/0qVAFj/eqCW6UrDL9uQqYZAV/WrMcjM+ABsXrVFoOVljZi2MAZ4FWIjhAHfDfzoDY0YZFYhcY44PrTtpCbmwCOnHaqSvuYbG/pVgO6nDPlR0yaQxCFCNyd1Y+q2N3dS2ZtL57ZIm3yIFz5g9M1fu5wrg7s56mowd8bM0gBx3pjsSrJmZVbdgfrVkTKp+U7yDyOwrOV9rZLkjpxV0S/u8beo9OaGO1icTuSGCkHoD6VDcTSHAUHce9NE5YdMHoADSFnZtzYVs/LgZoEV/I3gb/AJcDJBqxGm0qzYGB8q+tPVFB/eMWbFWILYyIC4YMRkjPT2pXAIGxyFJXsMVOo2ZkkHPoOTSiN1IC7hjv/SmvIUVsAcdST1qQFuH+RTsLDoB/jWfcXHzmNflUD5sd/pTprt8FVHyen+NVnQb05HmMeBngVQLUmij8wZjzzyAxqQFY1PygN0J7mpUQRxMeAQMlu9U2kWVlZFcDr83H5+9Ax+7aoVRlj95j1FNmwoUHgHnA60zcQMjgkYVQe1RTPvdg3UDgZ6D1polsWeUMcHjjLcdB9aqzMSPlY4b7qjoBU0SrNa/vkIBOcAdfSopGEYyTgj7p70XJvcTCwqC/JH6mkAkKbs4Zup74pm1iI+47FuePWpLlgoXbjDdXz+WKYmykYTGSI1kZeuRRVdj5jFg569hnFFUK7MhsgjB5pTnHU5z2FN/hySKRSRkjGe+a+pPjhyDJ6jOKr30Y+Rhzzg1YZu4x9KjmXdG2epHBFZVo80GjahLkqJmefvfL1/lVqFvl2tgn071TXIbgng1owDemRgEdvevDmrH0MGXbVlMYBwT2q9sI2spIIFZ6HaoGMkHrWlbSBjhuCOM1ibIY0r7sl+VNMO4yMwyynkVelRCOO3f1qssnlNtAzzkmkaLUImePqCR1GDVxJ94O4FRnnNMhnUFl2DLdMjp71C8TgnZ0PJwc0rjsXLdwXOZCefuY4A9c1YifKHaBuPGCKoqGVgSc/hUgOAGYkADmlYC4ioT88QIPBJpIUwMZC++OtVw7BArFmDd8dKkjK+WdgJxxmixSZpvAHhBjY5HPFVZuAOQsp+4SM0RNIU2Zwcc0GXcMDOTUlIQooCSMCzEbSAelOe4ABVVbP1pjbt4bO0DtT0RSRyAT6UAU5VL4zjOeRmlR3yVYBgO1W5IIgpUpuP8AKo4oFjAQcgnI74HpQUSQR/LuIxn9KtRqu9dzdBxVdmRW2EnI7ihXQDOCT6jvSE2TuIlBLDGevYUyMsTnJ47etRBZJhgt1OfWrMEK4IclVB9aARctkGwlc5J6nrU4kCHYoz3OKeVMUYKc4GR7+9UnZmcKpG4/eOentS3EWncOgU/KTVWeDzDtDHFRu+ZHKr0HWno+yPafvEZJp2FcjWNEhYiM575PSo4EcDfsBJ/DH0FTM6rF8oAUd/WiNsJnv1p2DYYz7EOckDrWTLfSs7iONWXI5Y471cuWwhAOd56dqgYbVKRgFunrRYTY6RmJJTAGMZ6n8KiizLI5wFiHG/8Avepp2WiiCcyOxySOKbbxiAFRuwCTtznk0bEsld1EWUAIA6eo+lVsmVcldxHTPb3qWI72kZ8hVPLds/1od1i/1YJDcknsKLCSI1Pm26lgV3HueoqtcSBtrbRwMDvzU0hEm2QDPBC54xVGeUHJAIXHbqfYU0BC24scAn6UU3b6jn60VYGXwTnHekIOcU7kgHt7UEk/UGvqD40Fxnkc0ADdg5FOXB4I59aawPfigZmONsjZ6Dg1Zt2YbCpycc+4ptwgEpzyrDOKWI8ADt614daPLJo+hoT5opmtEVI5wR1qRCC25fXmqKvtTg4J6VatmO0HOG7nHBrlaOyJopIrIF53elQyAggqMkccCmDJbIB9asRM5Chl/GpLV0NRmVyOm71q1jCbwQMdQelROFYEjkk/lUsJIBH3TjGCcikVcnIV4+COehAqpKMyY3bSOhBqcOU+UgfhUbkbwpGSaWwye3+ZgpGR71dS2YE+Wvy98d6zrYoWOWJXpg8YrUt5TtGeo6kdSKTArywFSR8wyOlLCNhAHzY4q3MA45zz6VE+3uOnTFK5aEEZc5YjHQVLbhRncASKhEnl/MxyD92nxyBlznGefxpO47E8gVTujHzGqoVg4JB3ZP41YXJBbJJ6U3y8FdpJz1agaEYlEwFDNUkUB4aUjA5A9aGK43OPu8emaElZ9zcBB7daQEsjqBn5c9vYVFEwdgFbcQcknims6uu3byf0oEezrgewFNaCLvnSSZjRiIuQTnk1AkCRlgowWO52yeTTCVIBRsspxz0zRI7MuGOOOtAhd4JPljIX+L0pj3JMpRMbsfNSosjJ5cWMgdxQIQq7UXc/dvU1SsIYSZAyAdOvvTZp8mODaQ3UdhipC210Usoz196ZIm/5wRv6ZHpSuJsiKjPQ8cVCoYtlMqhOSfSrSxoEO5gQF5ANKo3Knl8IOnFDkRe7KRZjNjDZB4PTANWDFucKpXaOlMaJ4XZjjzG6k9Rn0qWMFRjH3RyxNF7lCyMqEJ0PY+tU55E4O7GDjJ9PpUsxYlGyC3rVKYKFPzHOcA+vvTEMncLy4IT6/Nmq24EcgYPGR/KnPiRxtJ+Xpzj8arudm1sFj6f0poTYSyAPziioy4BwO3XjPNFMV0Zp4Pr+NSHAJyeaiXqdpxmngc5A6da+pZ8cKckA8ULyOTn2ppOTlRwRzSrgEZ4HtQMhvRgB85xxUUbfdPb1q1Km9HXsRxVKIAghuvr6V5uMhaXN3PWwFS8eXsXrdgr4Iyo/SrcQw2FGUP6Vnwkrzjt0rStyFTqACO3Y+lebJHrRLcD74x5ieW393OcfjVtFSNCQMk9+uKz0bdkMQcVahk4GM59zWZqieAAOfl5608xp+8ByA3Xmq6S/OcnipgEZc7Tz156UrC6jlAVgpc4UcEmkeEEgsRuB470eWo5JOO3NPVdh3Y49M5FDLuQtuTIABb371dhI2Z6cd+ahmQNGD1z+YpIyyYIYDB54qRo00G3qGAIG3JpWCb1ULk9zUKP5gUtIDjin5IBJGD7VJSEktN785KdhnkVALchwEcuM/dxirikggr83pTvur8wxnv3plrQgMjJ1YDHGBTVJKkqpYep6USMgIwMipYl8xtigAD070guQh2C4UcenXJq5CS0a7gMenemmBsBYk3YIBxgcdz+FWlRUO3rgYyTQ7AxgCnBIzinThWTEoBB7ComnETHCkhuMGpNyk5UYJHSghkaxAISuEA/lShUkcLx0496dIWkTEgwR2HeiDlDwI2P6e1Ah5UKuN3J6CqskgQBFb33DqalQ4VxvLYPVhSqBs+4CV/QUAUBGXB8zjB4BPNOBSOMAgcDAH92pzGWuGKrk461OtlGqglgcHJBHei5LVyhFbyvGXchIieg4zVjaWlBQHaBjg0pkaZzGEyinGR0qRsqWAHycLikgsIsYZhIAA3Qc/rVO/iLo6RsUB5YgVaVPLDs7/MeMe1QXD7jgdOrewqku4bFZUEUSnB54HOcCsu9kbzsqoIPKjOPqTV65kUJgZxiqEfznIACDufSmtiGyawgFxJy4jjRDI7YzgD+dFoAbO5kjkHmBcuhQHKZ4IPrntT9PeX7STbvGFCMWMg+Tb33eoqK9kjFnKtvNYojY3JArbnx0GT/KrSM29bGaXCnGQKKjJ28Bc0UWKuVFHFBBJOOeKbk04Dg5/SvqD5EOQtOC7gSCCKYQDxzQvGT3xQhCnPXqBVJx5c5XAweavgcZyPaql8hCK/cHGa5sVHmhfsdeDnyVLdySJjkDggdjVy1YAE4LZPesuJuSK0oj90gV40z34MuglXAxx61IFxIqSnac9MU1B8nON1OnX5965VQwIyck/WsjeLHSHy2ODye5qSGYoxGFOTnjv9ac8aOwdgMelOWHL5BHpnFIslkKtGfnwDxj0pkR8tFDZLdM1I1thRtIU59aFznqCV4/CkFhfMYdVGKcoJ5Yg0zPUnOfX0qOZmAyu7cfakxl6I4wsfynqO9TBxjLMSffvWdDJ5qqAcP0yKsL88ZAI+X1PWiwJmgkw6YINEr5Jz6dfSqgBbGzt1Jpdx81sg8jAyeDUtFoapVpMNz3AFXUYI4VMlj1JqtEqDJYBu2VqwzYXIByO4OTRYZbt3GQH+Qjrk9aJJfm+Xbtx9aroVPzMvX1oG0fMpySefapsTcSaQKAW5P8KikWYb9qEZPJJ4qKZdxIUZb+8T2psVoT1b5MjI9apAW87oxyQufrToyQzAYA6UijZlVX5QMLnvSwo0rctgAZIHSgCXy+CwAOD0FI6MVyxwB2FDRsCqqx29TSPKFY55J6UhEyEIoAUZfqe+Kr3Ep35Q8Ac7u9RT3AIJY7Vx0qg8u8FgdqE/e9T9KBF0yorBd4CAfN7mka6A4UZPYdvrVC4nRUUBCyg8cZLGoZHm+XCcsMnJwFFUkS2Tz3o+bg7+gJ71VnumVSxyUHUn+I1XSJnLSSH5c4Pv6UJE0txl8NGvQDpn0pkjdslyN/IXsoOM/jUhbCdgg4zVuVPLZVwNgHzEetUZsckqVZsfLnt2oQaFywiuY3EyWUlxA6lGUcA5/wxUOoxiG2kdNKuISBnzXkJC5PpVGSdlb5ZGXHoxH5VnvNIUYtI7AnoWJFWjJxbdxpZ2JIYqBwAKK5vWtf+w3xgSPzNqjcc45PNFPlYcyOiXlSQDn0NHbjGKQZ/h7U7jaTX0zPlAJI6c8UYGRnk/ypSOCSD0oBUsBjgfrRcQq49vY0ydA0TL14yKlcggDoPSmDoAPzNJrmViovld0UIW4DKcMKvQNsIOMZGazyvlzMvXnirkEoA5Azn9K8GpGzaZ9JSkpJM1LOYnGccdcVadEcAK+XPpWbH8rjoF6VoRlVcAY6VznXElVOAGJI9KsxxuzBi2B0PvVOZyigg/P/AEqxAzMPvcmkaFsAiNg/XPA9KqFiJSMYXoKt4YqSSM44qGSMHLE9ByB2NIBjtleCD3PPUUkY+UbmIk9fUUfcwAAVOcmpAG2nCjA/UUrjJII8Ekc/NVryNiblbGTnpUUC5QtHgkcFelTK2+PBXf7HnpSYXIhgAgkbj1pXRnIVV+U8ZNSTqxCkIATSiP5MM+0+n+NA7kOPLYKQAFHODU8Mh3naBg4ycVC0eZxvO70ApAnO1AQpPOTSHqWmwzknGPTpQjx+Xg5wO570xmCIWLBsDAHemBS+Mg8+lIViXzd2SAADVpGCqGbkHgKelQAAbRGVGOD7e1TDa3LcY7DvQAqqF3GVjg9h2qZCDkEYUdAOrVB5qkE7treh9KrS3QQO2QpI5bHJpWuGhZuJyF25ODxtFUZZ/mdFQnsQBwKhimdgXJxnpj0pyTqiHDZJPGBVbE3C3Xe7M4Yk+tNnCyyBQPlA6dCxqREmnH3fLTvuNWIIki3GRg8nILeg9KBEEdiI1WRmB4zweg9BVbUFmkiaO0KwylflLcgenFWryUzuCCVH3QF4wPWqjKY1ZicoOOepPtTEyC1jMNpHFcSmaRB88mPvHufalR1RSCCAThfrTwy4Kqu0D5ifeqcspicYI+YdD0Hr+NNXJZJLKoRt2ACfzqlJPuldV3E92P8ALNPaRWYuxGMce1V5GJJaNhgj5eKZItpbC4ZsyLGscbSvJjOFHt9adfMui6Vd3X2p1uYbZbiaILwEJ4GfXOKNLdzcF4XWNUQtI7ruGwdcjv8ASuT+Jd/cSx6np9pfK5jWG7vFMe15UYDGD6LkfLWsI3MakrHCtdvcyPPMcySMXY+5orNikAQdKK35THmPZ1AAyTzTmO4DGB7U1R1z0FKBls+vrXunzorfd46j1oAAGDznvQOST/Ol4Gc/pSAQ7v1owCcClDZUnqKRunHHtTAoXwCSK2OGGKdCAwz3Hv1FS3qZh3cfLzVOI4brwa8nFw5Z37nt4KpemvI1oQSq5/yKtwOu1t2TjgD2qpZvyM9M4xV4Io5Tp0rgkj04SLSYdcHOaeg2Dkkgdc1ArERhsg7eM1KclQFbk84NSap3LZmL47rj060xcuuACpH8R70qP8gQABh7cUFmA5x71NxkjcDI7D0piMAFLH2+lTxumOW57AUkpCq2Ii5UZAA6mpuITzODhiQOmDT7d9oJzlSOCOKjYLsUKQGPWnR4YAI2fanoGpZafjglvfvTGmwrbsNuPTHNQs2OC2GHpTW527hkHnipsWiQybduDs9eKckcjuD/AA9uaVIyzBcLt9auwQkKSTn6UXsUVPLzJjknt7U4FVGEHJ7nt+NXpIeOfvHsO1QXGEUD7q980lqJsrFmUEHhfUdakicLGDgs7VXA+0I2WZSW6r/KrAMoKhiF9qZIyVnZsFguP4c8mmsgCHzAGZvxqc223JjKknlifWhyiYydznv6e9ArFQozAbnKp0x6mpohkBgu0A4UY/WnLFJK6h12oOnqfepiyqirGQODknr9aQxHleM4HIXoq9SaryHcUXhWOWKg9D7mm+ZubCoFboM+nrUb4jDkk5PQHrTJZJIpUKQQTzzVPzSyfKSoXJDH1oJaRip6Y7U2QKieXxvxwM9qqxLZDKVVdij5du4tjljVV1L4LsViH8PUtUznHzOCQemT2rKVnkv5SRPtJB3NwufRRTRDdi6QmGIPA/hqrOV3M2Mr/ntUjOo3IpYEZzVWeYbgFTIA4Gf1phcltJLhZiLdIpZHRgYpW2rIuOQT9K43xTYarem9+xWOnQfavLinnF+sjyKuNsYycDoPrWsbvGq/ZzDNcpPE0TpD9/5u6/SsvX9Kh0/Rrgiy1QwTbEup5YVj8qIOD8q55bOAD2r0aNG1Lm6s8nEV71uVbI87kSaGV4pImSSNijIeCpHUGip9avf7T1e8vhH5QnkLhCclR0GT64FFRY3R7HnOeDTwecg0wHnoaBXtM8AfzyDzTgflz1PpSLgkAHt1peuBn8DSAFJwRxjvQep6YPekXv3pM885FMQ/apiIPfIIrHKlHIJIKnFazE+nUfnVG8XEiv03D9a48ZC8eZdDvwFS0+V9SxZybcZ71qxYKAH8CKxLZu5xnoCa1oWyo5Iz79K8iR7kC7GcYVxnHPFSgAqCMe1QIrfLtJPOanLEHaRwBzzyKzOhEqtnaFbAI5FSKjcEkkfqKqh0LYI3AdCKnRiG3ORtIwu3r+NS2USxDL8kZHXjvVhN3RxgHuDxUMTB87lDDtxSiQFdqfMh42njFSIeCvmjADAd+maeIf3isCAewHWm4XODwVHA9qarEMSmc9KQyYIS3GAQecD/ADzU6xb2KgBARnNV45QSV3gle/vU8b7Y+nz9yaLFIsRpGoOMgnjrmn8JwnJ+tRoTuU8fiaiuJvK3FIyXzjk9qVriuS3E+z5Q2T3Oeaz7yZZOGc56Y7mknJkf0J6c9KjSPeThQDnk96pKwrjkkwgVjtUfw+tSLvd1ZQT3x2FTx2Xyjzc/N2HU1Z8tI4g4HygY20bjK53AKWfkH14prhmVhCyiQj5HYZwfpUzsE6qAnue9Vy+XYxgkE4z7+1ITZYknC4X1HIJxiqrseclto6YHWgKjNmRjwPwzTZTsXnOew9BQhXIACAQGYs/LY7ULFtkEkhyQO9KjeUWKjLHknPSoHlYJggDAyee9US2PeTarZAwDmqDuWuBg8H7wxy31PpUhZ3feQSh45p+3avmHChR370EtlC/ZNrNK+2McHnApkbZQMMhAON3aiWHzLlGLHyVBwpHVvWnEAHDnPfkVRO5Cf9W/GSw78VmTMIoxuJYk4B/n+FXZ5S2FYdOue9ZmpSbLWV27KRVRXM0hSkopt9DJ0u/jTULySac26zwyQiYAkxk9Dxz2xx61a1C/tLzRrgT3/mvPbRQ/ZDuLLMpx5npjHfvmq/hfc2pOI0j83yHMcsoBSFsffYHjA6fjVnU5NTbT5hc3+mzQkDckLx7jz2wM19BypWR8w5NtyPLbmM287xMRlTjkUV0d7YRXM29/vYwT60VzSwsr6HZHFK2p6KpJ7mpB39KjGQO9P6464r0GzzRccelOPJxj5v50icdefpQMZ9GFSMD945xxSgjr2pARk56UrcD/AApiAAnnJyar3qA25IHKnOasquACCKR4y6OuMAqc1FRc0XE0pS5ZqRlI53ccdCa1baUYx3BrHDYbH5VftycqUyD1rwZI+lgzbjk5XAx+NWYmC7s9Sc1nQyZVc5z/ADqxAw3sSx2jtjNYtGyZYBCyAgZ5qccY+YbfUdjVVZFVOcgg9QKeHwpaNep/A1LNbk8UhDqwbrwfQ1axuYjzCvHIx1qpEBtVVCqx6itC3x8+7rjhqkdysGj84wM25gMjd1qReWOFII7io4wklzIxGHXjJHapyc9DtYe1IGL5ACgqAAe3vU8GBEcncexz0oaIsUbp3+tCqQCWxigLgr7VZhnd246U145XAOwkt15qWIoyfeC46n1p6gAAhgAOuaAKXlnOBnjrirkECJHvwXIOQPSpY0j2bQOoyTTlUoeG+VRz70XuA/ziMOQCw4ANRSSr83PTkAVBNuwWUFRnjnJNVJZNiYY8n3z+FNIlyHTzGRsr908ZJ/lSoTjA+4oxk1VJwRlST29qfEHnOMEIDgY70wJo32koG5PfHAFMkUZGxu3JPJqUokbgKWJUc+magYlSVOADx9akGQNICCqZAI5LVGoLcfePp2/GpNm+VzCMk9SaUJ95FYDjnApolleSSKMKuQT3zVZ2bPEJ2Hnr1qYxCSVdvJX7xbn8Kc4NxdM5BCIdoHr7/Sr2JIVjAy756/gBVaYB2yw4BzVy6dY1cDHvWW+7apJJPfJpIbIrhiQdoDA9MdzXP6/Ky28cZ+853Ng9K3nJUDbwD3PpXM+IHJulz2XP611YOPNVRx42XLRZZ8O2F7vN0NOe7s5Y3iZVlVA4PBzntxT9U0pbfT5Zf7FurbaB+9e6V1XnuO9YkcM7KHjimdD3VCRTmgmjBZ4ZVjHJ3IwAr27anz99Cvx3Iop2V9M/hRVEna5Gcc5pRwc0mDk7Rn3oQgg5VhVEkg+6Tnk0oG7GTk+tMAxjPSpcAdDk0hjccE+vrSkg+nFGecHFDctQJjgRxnHHpQuVbsTSHheCDmheMnHbk5oYGI/yzSIedrH8KtWp28E5U9Kr3y7L6TI4bB+lPhIRsHoTXh1Y2m0fR0JXgma9o2enY9K0oShfq2PWsSOQq45wex/xrShmy4AA6c+1czOtFx0Gfm6dOOlWYI8xDaflHXjrUG/dtXJyO+ODT4WdJCNuVzwc/wA6llk8QaTdnawB4I7ip0faxVCM9f8A61VvN2EbQFP92l3F2Yx8OAByKixSLAYAN1D+vtTg3mOpDZPrUETvnHfrzRC5LDBAx2xTGXQVYCMseewqXaEBRf1qG3yVzgZ7Ypxldg4fscAnipAQEAfMuOeOetOQF0IIO71PamRlOCVBI79TUwKs24Bs478CgLj94WPZhlx3qN7oLgg7sUyRndAAu4se1MWGRhkngdwOlNWJ3EknLsC5yT7cCoAzF87RjsfT61aSH5snvzk9vrSbcEgn357mi40it5YLYyffPU1PF8kbMzAdsg1VvJ4rSNZZXAyduW7k9AKsKMx7WXdnnn/PSle4xwYbMucgfrVaQGUswK7cdzT5QT99wqg88foKdEqNkHDDqDijYQ2SLEQCnDMO3JqN8KCcnccDANXPJ+UK/wApzng8/nShB8zMMgH6cUXEzM+y75lmDEODghTgGnlBlw7E55A9BVyYbowo2qgOcN6VTl+620cscZPene4kilM28lZMcjOPT2NU3U43YIwMdO9aRtVEhYA7unzc5qFo22HeuODwe1UmGxj3OQqpnaepPcVy+ttnUCoxkKB+NdXcD+E49h71xmotuvZiTyWxXfgFepfyPNzKVqSXdmhoVzdFpI21K7trK3heeRYG5wMcKOmSTWprOxtOvEi1LVLl1hjm8ueQbCjY+Y+uM9Kx/DysL+SQTiGOGB5JW8sPlMYK7T1zkVZt7yS78OXcEciiW2Rd+Yhue33DC7/YnpXqtanirYwuR3opfk7iitCDtTkHPpQvXnketJ2IxxThx06UEjjjHrz1py5UetN255JzUmSRzQMTqc45pp5PrilA56YoYY+btTQg9AOM96Fxk5PT2pchhwfzpQRjr+FAGTq6/wCkRuB/B/Woo5AQDjPvV3VVwsTEcAkVmx5E2OmRkV42LVqjPdwUr0kaQwyjFWrViswBIwD0qlHkNzxnse1TQPsYFskY6+tcWh3o3ISH+VTjPXBq5HkHacscce1Ztq3zZHI9u1aEaIwUkscEkYPepZdyUIWA6EnjOP506ORQVixtkIPHtTJUJAHBHrUiENHuU7iO5PJpM0Q8dcluPcdaaF8skl+XO5Qe30o5dFCqrc9qRlLEZ/hHcc1LGh9tIXyNrKc5yKlbDkA4x1yarwJLgjcBkn/9VXYomZSGwB+lIYxVIcnJA6gipQnnZXhkI5OefypQS2flGwcA+tNUKgAx/wABHU0ElhSkcKxqAmBUKyORwQEPTFMcBMmRhk8BR2oQFotrcZ6jpStYfoLLKEAGSeM5NRiMvmUA47CpPLbuQT0x2xUsZ+QADg9BQ2BAEJ2AgbR+OKFdVL9cnjB6k1MziMjuT261TkZmlKsuSBu3DgfShaiIpI2d8EAp1OO/tVhdq8kleOmaZGOg34bGSe9PSPcCdpJPT2qmFwhD+Yd/3Oo7nFWCNzYQL06nmmc52qPm7k1LFGdp4BXpwevtRYLFeZDsCljuJ5x/ngVVkUIQeST0C8mrxj2tIFHBGOR3qIFQTjllHJA46UDsUbkFIWkLOT/dXrVGfIUfMQSKuTMWYluIs/Lk/eNU7jeZGJUlQMhj1oREjLvDlm6ZHUVxFwxN1ISRyxrsr4bOK4sndM5J6sT9K9XLlrJnk5m/dijQ0t0tbi3nXU4bZirbzJGXC9tjDHIYVe1O7t5NNljtdS00KxBaC1tmjMxB7k+nXFV/DEnk6k7K8KzGB1h84DYznoGzxW3Fda1DaTJqH2VbmRkS1V0j3O+7kEDjZjOSa9F7nkLY4057hTRV/WVtl1e8WzI+ziU7NvT3x7ZzRVpk7HTAksR70fxHHr3pRluMfjSgcNjsKokeAQvbmnJzjdyO1MB6DqcdqVTuGMUrMY8YKkY5BpjcAEZz1p6jkjHOOaQknt24PrQgEDEg5FOHB70hGcYyPXNC5IJOc07CK+p/NZE/3SDWREPm3DlegFbd6M2kucfd4FY0QyxHQdcCvLxy95PyPYy53g0XoeRx2P405vukqMD09KS2UDkYLe3epjt2H5j0rzXueoizp8m9cM2COcjtWnAx3/P+YOKw4wUfAIweK1YCSoLZwB0H9KTGjWi2BcKdx7+1WIowAzY69AOMetUYiAFB3EkZ9xVlJuAuS30qGaEuNqq8Sgqe4PNS7Q+WLBWP97mq6d1C/L2pY8Bf3mCOwFSUmSwh9x+7tz1zUzZLhc4jHWmwDaQcVaAVvlAyTzzSGQ7ByRkAcCnKhye3GAT3qRVwhBIAB9akkGDjI/KkMqmEjncSw5+tMEMjyCWYZccYBxgVcjVokQlWlZ2xuH8I9fpVhkVWY8E44HWi4FB25XcMD060oU4AA7ZqV1Pm5zjPJx0NTEY+XPygc+5oCxTdQqg5O48nAqiVLSjaSd3U+gq+YxgszZP90Gqpj3ONhKn0PariQ9RLdMSsXOMDjircCbVJJyME5JqFYwiOcFmHBqxCrPE3VemO/wCdKw7D4olMSqdpY9x2FJFHHDwjfMDnB/nUz/IqjPJ4HoKayMw+RcY9FoWo9io7KsjAbsZxkmqTkkkBtq+voKuOmwMGJ+bkHvVRiC2Exuz9c+9WK5UnCKu5lZgOQgGarXBbblj2/KrkgKnJclPSqF2xwQMAdvaghmDqkgWORz6E1xwY5z3NdJr7hbdiScsdozXNcAY5zXsZfG0HLueJmcrzUexqeHreK6vnEkAuHSF5IoCeJXA4X37nHfFXJA17pN/NfadDam3VTFNHD5WWLAeXj+LIz7jFc+soRwQ+xxyCDgitOKSTU7W/mvbuedrWESRbpCwUlgOn0NdrR5y2M4sc9QvtRTTtPUmiqJO3DdjnFKFOCN2cU0HipMEAk9aq4hQAMelKApHQ0ik4x1NLnOPUUgHDjIODSNgOTgbiMU8cDkcnvTBzmhagIeTzUq8Dpn60BQCN2KX2zn3ptgQ3QDW8uRg7DWBHn5GBwQK6O5AFrL/uH+VczGx8oD8q83Hbo9XLtpGrbckFeueoq5J1OQATxms6xYYwCR/KrIuVdiE5x1zXlyWp66HMp3AgAlRk+9bFthoEC4wentWPDtJAHBrWtekeSO5BX1qWBbiT5MMzE9yD0qyu5SSQCQOtJCMfeABI/OrMCoxDSEqRnp3NRc0QiAEhyccdB1qRX3fI0YZP4mzjNJG7JuOABnGT3pYxsASPOBgnPP61D3GLEmGZRwB0IPGKuIpwSxz/ADpi4AOT1ORUkbFm2Afe9Kd7lBIoIQL3Oc09c4OTkjge1O2EEgDJB6UyMgO+Bg9BmkMtxuDtG3G3t2zTk+eXIIJ7egqEbtzEsB9asB9sQcED39Kl3AaYgcjB461DL5aIm4dz0NPeYthQMkHOarzNlSpbn6VSTE3Yhmk+b5AMVFDCzFXPJJzgdamVE3bcfMB1NTRL5ce5Tgdj6VZNhI7dnyG4xz71Kqqm7k5IwAelPjmBXcBu470ySRchhjB4xQncY7ZtXcoZmHfGOaju7hEKncqsQSVHWmSSsCo3Hy+pPqaqzKMu7jL9j6imkK5DPJ55UKMKvUjvRMFhDfux8vdev4/4VDJJzwSB39qQPCqYL7i5Jyxzj8BVcrYr30KtzNuJVRuOenpWdegqhYEAnrn0rSnZeXK4XsG71g6hcEKQcYNUog9jltelDyRxgkhcmsjJz83fp71ZvpPOunYHIBwPpUGORxXvYeHJTSPmMVU9pVkzStNdvrO1WC3aARrnbvgRjyfUjNOuNe1C7t5IJpITDIMMEgRSe/UCnafDpUunTSXa3Ru4TuZElVQ6E4yuR1HcfjUNy+leRILSC+Sc/cMkqso+oArXTsY62M8YxxkUUcepoqiTtlGB15PapAOpzzUZBPB596euCvPFMQ4cHpnIpyjgknBxxQhIHanY3dgB/KlcBoJBHFO4PsaXHzH1o+XqR9R60wFXA4Ip1NGRg9RTx8q/zpMCG4z9nlz1KkfpXOQqChXiukuW/cueh2n+Vc3bjgehrzsd0PUy77RbtCFwR2zxUyAO+4LxjrTLPgtwSRzmrKRhHbB4IrzG9T2EPiTac4OPWtOAARpjPB4rMQ/wjJOfWtSzborDdjBx61DHsa9uSypyenapY1Pl7mYhhkdKrW6lZGIzgnpVsguwCj5TwcnrWbLQ6DBfBye+T61ZaPDEFgVPbHSqojbzdhB2qM5H8quRguqkBlGPTpSZVh6gsgQHAXuKkhCRM7YPmSDlqFUhSyYOetKfm6JnIx16Uh2EVyy8McZ545pYJFkJK4PPQ9qRYwWJORIox7UKjj+EZ+lAiWLodhJAPU80swfyyc7WJ+7SRvhHXoR6elMd92DuOVOeRmhIYbmjb5xzjrUMrhm3KSSe1PdzO/6dKa2I8FeT0HpVoVwjVVy5GCRSuzFht6EdOhqt85B81lLk4BAxVq2ALDAJYdzTaAWJMoMk8D7xqSSKMDIwBjr15pv2hCpGN+R2HFNVkjTL5ySTjqaAAqBjHLDqCf8AOKzNSvEDAxg89h3NWZpl2Hbwfz/OslrZ5UZghOThmI4A9qtK4rXKol8wEtgKM9TgZ9vWrENxJ5QIO1D97aoAJ/3qieHyVLER+WOpPUfhUFzKCoDO7N12n1+lbKxpokNvrjYrFHOfX7361yms3mxMLzI/HsK07+5RVct0HNcheXJuJy7H5egHoK6cNR9pLXZHm47E+yhZbsixjJxn8aORg460nG3rmnN93nBI6V6x86aljpltdaY93LqHleSQJUFuXKAnhuD0Pr2plxb6ckDvb6n50v8ADF9mZd34k8U63trO3sIbrUJ7ofad3lw2wGWVTglieMZ7UPaWFxaXU+mS3KyWyh5IbhRymcZVh3GRwakdjKIAPQ0UHd7GirEdznJHUGngDOcVH7A8etOHHHUUMQ88Hr9c0q8cCmgEnp2pSegIINADgd3C8U8D3yfrTMeox/WnRt833R/hQA5fvcjIoAJYnn8aaBk4z05qQDjHUmmwGzJuhkBxyD+HFczaMSq9OnQ966phhSB6Vx9vgpsbOA36g152O2TPUy/eSNS3BUbx+I9atO+5MqeMGqsLknPr/OplxsKjgmvKZ7CJoU3YBHPc1YtGPmYUEkYFQ2ZODzyRgj9KuQIwxt4OakZs27lkYE9jhqs2wb5dwII6H2rPiYiPJJ5bnjNatpyoJUhewPc1LRSJArZJBJJPHant5pXGSV7qO9RncJEKqSR8pAPAFXLSaOSQx4LeXgHjHWoZotByIw6dhngVMqjcCCcgcj3pAnlI3lk8n60BvLyAQS1SLcbKEOCW6HHWkhffK+VIC9GzTZNinO05PY9aRYhszHnaB09KqwEpYndlTyepH61FGN7jjdjgEHg1OQPKGOHxyDQnyjDLhgOCtUgE/wBUpGMFupqldTrg8qAOM1NcyZQ5yV9M1nFgWx1wapIlsnUqG+ZvmA/Kp4p+dgZQPf8Aqazl2uWJIUE8k9MVbROctnnkMaY0rlmUOpAiwR0LH+g7VDIGWQnJJx0HWrAHyDDbX/M4/pUTKNx2sSehXPH4mhFWGRw74nKsOpJz2qC8PlLsUuvfHU/U+9aCodhzgDjAHes2/ZAr7nIK9vT/AOvVLVlbGJdhlyQF98nOKoXMhVTuP7wDBNWNSn/efMAAB90dzXL6zqDKCob526e1bQg5NRRz16qpxcn0M7WLxpJGjU/J1OP5Vm5yD9aG5IOcmkwMjJI4r26VNU48qPmK1V1puTFXHPakB+bvjvSE88jmlBx1FaGR0ejC4GmxiWfTVtZZG+zw3y53N3Kn+EZ4znGajuXv5bfUrZ4LawjtFWSeGKHaZDuwAT3HOfSs571JtKitJbfdLCx8mYNjCk5ZSO/PSrS62X0i4srmHzZniWFLnPzBAwYK3qB2PWosx3MmilJPtRVCO525HUZp2BszgZ96VAMd805QCeBx2ouAoGF3E89hSHnIPOaVR2p20HJ9KEFhjA4GelPXABBOT60oGSR1pCOCvNO/QB4XnPGcdaDksPT1poOAADwad05x2xSYDs89K5IIEuZk9HP866o5A7VzFydmqXC443muLGr3Uz0MvfvtFm3G1icZyOpqyhyAQORyKrxkY254xwamjwOM49q8lntly1G1yenNatuoMSjqM5rMjGdma17ZC0YQdCcdOlQNFm2AL7TwqDPvWugXyl5Ix+tZYVVwDgc45rShBWLC4yT0qWi0OSJidykr6jsauRAqp+bPP4ioI1LRpnG7qewpytsVlHLfrU2uUTBtzjLfKTxj+tRyMBxEinb/ADp4bKgoPbrVZgyOAR8rE8g9KfKA/wAwvhy3K9e2asW0nzMOATVIeYSD8p9alDgnAP3upHWiwrlmXe8gCBQvdvWk3osZJbkcc1BvALbei8YNQzPhAq855JzmmkFyG7kO4EMTnoKqxL5ku0ksG54p0xIDY5c96ktUEYXI3M3JP9KrYSV3qWNvJCICAO/f/wCtU4LEryNx53H+X0pqlzsDDC9Q2P51K3O75QzDoCOQaW5qkIRt4UDOOQT1psjbV7AHuB/nFOM2xQQRuHUH+tROVkYlizE+3Aq0mAx3bYWL/J3/APrVhXl785RFJyMbcda0dRn8olFZi/ZAe9YNzi3VmLYkOckHpWiM5SMy/lKIccuep9K5C8kEty598da3tSmCQM54AGFHqa5tjxkc+1ejgobyPFzKrtBeo0cEk/pS554HNJ24OO9HIIAx+Fd55IqnHGKXjPHWkGcmgAdwc+tAG1aW6W+lm7aOCScp5oM6llRd21QF7sxB5PAAoubaO70r7WqQJOEMuYF2KQpAdGXsw3KQR1Bpmm6hElsLe6YptBRXMQlRkJzsdOMgHkEcinX2oRNatBanfvXYWWLykRM5KonXk4JJ5OKnW5XQx93qaKcetFWI/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fibrotic changes resembling cellulite are present on the leg in this patient with eosinophilic fasciitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5681=[""].join("\n");
var outline_f5_35_5681=null;
var title_f5_35_5682="Abnormal pancreaticobiliary junction II";
var content_f5_35_5682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormal pancreaticobiliary junction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in an adult with obstructive jaundice demonstrates an abnormal pancreaticobiliary junction with a malignant biliary stricture replacing the cystic duct insertion. There is no evidence of a biliary cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark D Topazian, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5682=[""].join("\n");
var outline_f5_35_5682=null;
var title_f5_35_5683="Sarcoidosis";
var content_f5_35_5683=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sarcoidosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/35/5683/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5683/contributors\" id=\"au4823\">",
"       Talmadge E King, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/35/5683/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5683/contributors\" id=\"se7122\">",
"       Kevin R Flaherty, MD, MS",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5683/contributors\" id=\"se5724\">",
"       Peter H Schur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?5/35/5683/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5683/contributors\" id=\"de1810\">",
"       Helen Hollingsworth, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?5/35/5683?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Sarcoidosis is a disorder that causes tiny nodules (granulomas) of inflamed tissue to develop in the body's organs. These nodules can join together, forming larger nodules that interfere with normal body functions such as breathing. Sarcoidosis almost always involves the lungs, but it can also affect the skin, eyes, nose, muscles, heart, liver, spleen, bowel, kidney, testes, nerves, lymph nodes, joints, and brain. Granulomas in the lungs can cause narrowing of the airways and inflammation and scarring (fibrosis) of lung tissue.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause of sarcoidosis is not known. One theory suggests that it develops when a genetically susceptible person is exposed to specific environmental agents. Although the specific agents are unknown, several organisms, including viruses and bacteria, have been suggested as possible causes.",
"    </p>",
"    <p>",
"     Noninfectious chemicals in the environment, including beryllium, aluminum, and zirconium, can cause lung disease that has features similar to sarcoidosis.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     Sarcoidosis occurs throughout the world, affecting both sexes and all races and ages. It is most commonly found in people between 20 and 40 years old. In a small percentage of cases, more than one family member is affected. Black people are three to four times more likely to have sarcoidosis, and may have more severe disease than people who are Caucasian. Sarcoidosis rarely occurs in children.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS SIGNS AND SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Sarcoidosis frequently causes mild symptoms and resolves on its own. The most common symptoms of lung involvement are cough, shortness of breath, and chest pain. The chest pain is usually no more than a vague tightness of the chest, but can occasionally be severe and similar to the pain of a heart attack. Affected individuals may also experience fatigue, weakness, fever, and weight loss. In approximately half of all patients, the condition is detected before any symptoms develop.",
"    </p>",
"    <p>",
"     Other organs in the body can also be affected. The signs and symptoms in these organs depend upon the site and extent of organ involvement (eg, involvement of the lungs can cause breathlessness or coughing). The following organ systems are commonly involved.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Skin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin lesions of different types can occur on the face, neck, arms, legs, or trunk. These lesions range from subtle, painless rashes to deep scars. People with more severe disease involving the internal organs often have more severe skin lesions.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Eyes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Involvement of the eyes can cause inflammation of different eye structures, including the iris, retina, or cornea. Glaucoma, cataracts, and blindness are late complications of untreated sarcoidosis. Because some sarcoidosis-related eye problems do not cause symptoms, it is important that all patients with sarcoidosis have an annual eye evaluation that includes an examination while the eyes are dilated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Kidney",
"     </span>",
"     &nbsp;&mdash;&nbsp;Abnormalities in the way the body handles calcium can occur and, if untreated, it may rarely lead to kidney failure. Small nodules (granulomas) may also develop in the kidney, leading to abnormal kidney function. Patients with sarcoidosis should have kidney function testing (usually with blood",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     urine tests) as part of their initial evaluation and follow up testing.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Heart",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nodules may develop in the heart, interfering with its electrical conduction system. This can result in abnormal heart rhythms and even death. An electrocardiogram (also referred to as an ECG or EKG) can generally detect abnormalities in the heart's electrical conduction. Damage and scarring of the lung and lung blood vessels (called pulmonary hypertension) rarely makes it more difficult for the heart to pump blood through the lungs. This condition can lead to failure of the heart's right ventricle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Nervous system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Neurologic involvement affects approximately 5 percent of patients with sarcoidosis, and may be the first sign of the condition. In the late stages of the disease meningitis, or inflammation of the membranes covering the base of the brain, it can cause impaired function of certain brain structures, including the pituitary gland, in addition to facial weakness or paralysis. The disease may also affect the nerves in the arms and legs, resulting in muscle weakness, numbness or tingling, and pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Musculoskeletal system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ten to 15 percent of people have musculoskeletal involvement, resulting in joint pain and swelling, changes in bone structure, or muscle discomfort and pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Reproductive system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sarcoidosis can affect the male reproductive system, particularly the testes, and may cause male infertility. The disease rarely affects the female reproductive system. Sarcoidosis does not increase the risk of complications during pregnancy; however, the disease may worsen after the birth of the child. Therefore, a chest x-ray is recommended for women with sarcoidosis within 6 months after delivery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Other organs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Enlargement of lymph nodes, especially those in the chest, occurs frequently. The liver or spleen can also be affected. Involvement of the spleen may lead to anemia and other blood abnormalities.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Since there is no single test that confirms a diagnosis of sarcoidosis, the diagnosis is based upon multiple factors, including signs and symptoms, abnormalities on chest X-ray (or CT scan), and microscopic examination of one or more specimens from involved tissues or organs. In addition, the diagnostic process often involves tests that help to rule out other conditions, including tuberculosis, which share some features with sarcoidosis. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"      \"Patient information: Tuberculosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     A biopsy involves removing a small sample of tissue from an affected tissue or organ. This test is usually recommended to identify a granuloma. Samples can be obtained from lung tissue with a procedure called bronchoscopy. A biopsy may also be done on an affected lymph node, skin nodule, salivary gland, or the tear gland near the eye. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"      \"Patient information: Flexible bronchoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Once the diagnosis of sarcoidosis is confirmed, other tests may be needed to determine the extent and severity of the disease. This may include imaging tests such as an MRI",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     PET scan to determine if there is evidence of the disease in the eyes, heart, or other organs.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Because the cause of sarcoidosis is not known, there is no specific treatment. Some medications are effective in suppressing symptoms, and these are discussed below. Fortunately, many individuals with sarcoidosis require no treatment since the nodules (granulomas) gradually resolve and leave behind few, if any, signs of inflammation or other complications.",
"    </p>",
"    <p>",
"     There are many questions about the best time to start treatment for sarcoidosis and how long it should be continued. Treatment is usually recommended in patients with worsening lung problems, especially shortness of breath and cough. Other reasons for treatment include signs of decreased lung function (as determined by pulmonary function testing), or difficulty functioning due to fever, weakness, fatigue, joint pain, nervous system changes, disfiguring skin disease, or disease affecting the upper airway. Sarcoidosis affecting the eyes, heart, or kidneys is treated even when symptoms are mild because of the potentially serious risk of complications when these systems are involved.",
"    </p>",
"    <p>",
"     Current treatment is focused on improving symptoms, suppressing inflammation, reducing the impact of the granulomas, and preventing the development of lung fibrosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Glucocorticoids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids (also known as steroids), most commonly prednisone, are particularly effective in reducing inflammation and are typically the first line treatment. In patients with mild disease, such as skin lesions, eye inflammation, or cough, topical glucocorticoid therapy with creams, eye-drops, or inhalers may be sufficient to control the disease.",
"    </p>",
"    <p>",
"     When necessary, oral glucocorticoids are generally taken for 6 to 12 months. A relatively high dose is usually recommended at first, followed by a slow taper to the lowest effective dose. Relapses may occur after glucocorticoid treatment has ended, although this usually responds to repeated treatment with glucocorticoids. Patients who improve and remain stable for more than one year after glucocorticoid treatment have a low risk of relapse.",
"    </p>",
"    <p>",
"     Symptoms of sarcoidosis, especially cough and shortness of breath, generally improve with glucocorticoid therapy. However, there are potentially serious side effects of long-term glucocorticoids, and the benefits must be weighed against the risks. These include increased appetite, weight gain, acne, fluid retention, trembling, mood swings, and difficulty sleeping. If glucocorticoids are taken for long periods of time, particularly if high doses are used, there is an increased risk of developing diabetes, thinning of the skin, easy bruising, a \"cushingoid\" appearance (widening of the face and a hump in the back), thinning of the bones, body hair growth, cataracts, high blood pressure, stomach ulcers, avascular necrosis (a serious joint problem), and infections. Because of the risk of these side effects, most patients are tapered off of glucocorticoids as soon as possible.",
"    </p>",
"    <p>",
"     Researchers continue to examine the role of glucocorticoids in the treatment of sarcoidosis. The biggest question is what effect these drugs have on the long-term course of the disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Other therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other therapies may be recommended for people who cannot tolerate glucocorticoids, do not respond to glucocorticoids, or want to",
"     <span class=\"nowrap\">",
"      avoid/reduce",
"     </span>",
"     glucocorticoid side effects.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Methotrexate reduces inflammation and suppresses the immune system and may allow for a lower dose of glucocorticoids to be used.",
"      </li>",
"      <li>",
"       Other drugs, including azathioprine, leflunomide, and cyclophosphamide, are sometimes used in conjunction with glucocorticoids if the condition is worsening despite treatment. These drugs work by suppressing the immune system. There are serious concerns about the toxic effects of cyclophosphamide, especially cancer, which have restricted its use to patients with the most severe disease. Some antimalarial medications (particularly chloroquine) have been used to treat sarcoidosis affecting the skin or lungs.",
"      </li>",
"      <li>",
"       Colchicine, a medication commonly used to treat gout, is sometimes prescribed for the treatment of sarcoidosis-related arthritis. Colchicine is an antiinflammatory medication that helps to relieve pain and swelling.",
"      </li>",
"      <li>",
"       Nonsteroidal anti-inflammatory agents (including ibuprofen) may help reduce inflammation and relieve joint pain, swelling, and fever, although they are not recommended for the treatment of sarcoidosis affecting the lungs.",
"      </li>",
"      <li>",
"       Methotrexate, hydroxychloroquine, and azathioprine are discussed in detail in a separate topic review. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"        \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     A cardiac pacemaker or intracardiac defibrillator may be needed in patients with cardiac sarcoidosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Tumor necrosis factor antagonists",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tumor necrosis factor antagonists are medications that were originally designed for treatment of rheumatoid arthritis. They work by interfering with the production of certain proteins involved in inflammation. Drugs in this class include etanercept (Enbrel&reg;) and infliximab (Remicade&reg;). Both of these tumor necrosis factor antagonists have undergone preliminary study as treatments for sarcoidosis when it has not responded to glucocorticoids, methotrexate, or azathioprine. However, results of these studies have been inconsistent.",
"    </p>",
"    <p>",
"     Anti-TNF medications may be used alone or in combination with methotrexate, azathioprine,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     glucocorticoids. All anti-TNF treatments must be injected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      SARCOIDOSIS LONG-TERM OUTCOME",
"     </span>",
"    </p>",
"    <p>",
"     In many patients, sarcoidosis resolves on its own or does not progress. In other patients, sarcoidosis may progress over many years and involve many organs. However, the overall death rate from sarcoidosis is less than 5 percent. Death most commonly results from progressive lung scarring, sometimes complicated by right heart failure or bleeding from the lungs, but can also result from sarcoidosis involving the heart.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804485486\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13673412\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/14/20705?source=see_link\">",
"      Patient information: Sarcoidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/24/20866?source=see_link\">",
"      Patient information: Erythema nodosum (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13673427\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/14/32993?source=see_link\">",
"      Patient information: Flexible bronchoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/14/17638?source=see_link\">",
"      Gastrointestinal sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"      Hepatic granulomas",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6376?source=see_link\">",
"      Pathogenesis of sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40438?source=see_link\">",
"      Renal disease in sarcoidosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11463?source=see_link\">",
"      Sarcoid arthropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25752?source=see_link\">",
"      Sarcoid: Muscle, bone, and vascular disease manifestations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/11/38074?source=see_link\">",
"      Treatment of pulmonary sarcoidosis with alternatives to glucocorticoids",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sarcoidosis.html\">",
"      www.nlm.nih.gov/medlineplus/sarcoidosis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/sarc/sar_whatis.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/sarc/sar_whatis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Lung Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.lungusa.org/\">",
"      www.lungusa.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Foundation for Sarcoidosis Research",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.stopsarcoidosis.org/\">",
"      www.stopsarcoidosis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Arthritis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://ww2.arthritis.org/conditions/DiseaseCenter/sarcoidosis.asp\">",
"      ww2.arthritis.org/conditions/DiseaseCenter/sarcoidosis.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?5/35/5683/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 22, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?5/35/5683?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/1\">",
"      Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005; 43:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/2\">",
"      Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/3\">",
"      Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/4\">",
"      Burns TM. Neurosarcoidosis. Arch Neurol 2003; 60:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/5\">",
"      Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; :CD001114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5683/abstract/6\">",
"      Thomas KW, Hunninghake GW. Sarcoidosis. JAMA 2003; 289:3300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f5_35_5683=[""].join("\n");
var outline_f5_35_5683=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SARCOIDOSIS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SARCOIDOSIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           SARCOIDOSIS SIGNS AND SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           SARCOIDOSIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SARCOIDOSIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           SARCOIDOSIS LONG-TERM OUTCOME",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5684="Fenoldopam: Pediatric drug information";
var content_f5_35_5684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenoldopam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"    see \"Fenoldopam: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corlopam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1013603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Dopamine Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1013629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"      see \"Fenoldopam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.2 mcg/kg/minute; may be increased every 20-30 minutes to 0.3-0.5 mcg/kg/minute; maximum dose: 0.8 mcg/kg/minute (higher doses have been shown to worsen tachycardia without any additional blood pressure benefits)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 0.1-0.3 mcg/kg/minute (lower initial doses may be associated with less reflex tachycardia); may be increased in increments of 0.05-0.1 mcg/kg/minute every 15 minutes until target blood pressure is reached; the maximal infusion rate reported in clinical studies was 1.6 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for renal impairment:",
"     </b>",
"     No guidelines are available.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corlopam&reg;: 10 mg/mL (1 mL, 2 mL) [contains propylene glycol, sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1013634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For continuous I.V. infusion using an infusion pump; dilute ampule contents in NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W to a maximum final concentration of 60 mcg/mL for children and 40 mcg/mL for adults.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     60",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3068095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aminocaproic acid, amiodarone, ampicillin/sulbactam, argatroban, atracurium, atropine, azithromycin, aztreonam, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin lactobionate, esmolol, famotidine, fentanyl, fluconazole, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;),  hydrocortisone sodium succinate, hydromorphone, hydroxyzine, inamrinone, iodixanol, iohexol, iopamidol, ioxaglate meglumine and ioxaglate sodium, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, metoclopramide, metronidazole, micafungin, midazolam, milrinone, morphine, nalbuphine, naloxone, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, pancuronium, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, promethazine, propofol, propranolol, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, sufentanil, sulfamethoxazole/trimethoprim, theophylline, ticarcillin/clavulanate, tobramycin, vancomycin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, bumetanide, cefoxitin, dexamethasone sodium phosphate, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone sodium succinate, pentobarbital, phenytoin, prochloperazine edisylate, sodium bicarbonate, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1013618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 30&deg;C (35&deg;F to 86&deg;F). Must be diluted prior to infusion. Following dilution, store at room temperature and use solution within 24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1013604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term reduction in blood pressure (up to 4 hours) [FDA approved in ages &lt;1 month (full term or &ge;2 kg) to 12 years and adults]; treatment of severe hypertension (up to 48 hours), including in patients with renal compromise (FDA approved in adults); has also been used for augmentation of urine output and prevention of acute renal injury in critically ill patients  (for 24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F170219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, bradycardia, chest pain, cutaneous flushing, extrasystoles, heart failure, hypotension, MI, orthostatic hypotension, palpitation, ST-T abnormalities, T-wave inversion, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/fullness, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding, leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, limb cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1013608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity of fenoldopam or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10484464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with glaucoma or intraocular hypertension; dose-dependent increases in intraocular pressure has been reported. A dose-related tachycardia can occur, especially at infusion rates &gt;0.1 mcg/kg/minute; in pediatric patients at doses &gt;0.8 mcg/kg/minute, tachycardia has been shown to persist for at least 4 hours. Close monitoring of blood pressure is necessary; hypotension can occur. For continuous infusion only; no bolus doses. Use caution in patients with increased intracranial pressure; use has not been studied in this population.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10916288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause hypokalemia; monitor serum potassium at 6 hour intervals during therapy. Contains sulfites which may cause allergic reaction in susceptible individuals, including anaphylactic symptoms or asthmatic episodes. Fenoldopam contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies; however, safety and efficacy have not been established for use during pregnancy. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1013636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, ECG, renal/hepatic function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1013621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A selective postsynaptic dopamine agonist (D",
"     <sub>",
"      1",
"     </sub>",
"     -receptors) which exerts hypotensive effects by decreasing peripheral vasculature resistance with increased renal blood flow, diuresis, and natriuresis; 6 times as potent as dopamine in producing renal vasodilation; has minimal adrenergic effects",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10484465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Children: 5 minutes; Adults: 10 minutes;",
"     <b>",
"      Note:",
"     </b>",
"     Majority of effect of a given infusion rate is attained within 15 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of effect (after stopping infusion): 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1013623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via methylation, glucuronidation, and sulfation; the 8-sulfate metabolite may have some activity; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: Children: 3-5 minutes; Adults: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (90%); feces (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Children: 3 L/hour/kg",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1013637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fenoldopam infusion can be abruptly discontinued or gradually tapered prior to discontinuation.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hammer GB, Verghese ST, Drover DR, et al, \"Pharmacokinetics and Pharmacodynamics of Fenoldopam Mesylate for Blood Pressure Control in Pediatric Patients,\"",
"      <i>",
"       BMC Anesthesiol",
"      </i>",
"      , 2008, 8:6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/35/5684/abstract-text/18837982/pubmed\" id=\"18837982\" target=\"_blank\">",
"        18837982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moffett BS, Mott AR, Nelson DP, et al, \"Renal Effects of Fenoldopam in Critically Ill Pediatric Patients: A Retrospective Review,\"",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2008, 9(4):403-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/35/5684/abstract-text/18496409/pubmed\" id=\"18496409\" target=\"_blank\">",
"        18496409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15983 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5684=[""].join("\n");
var outline_f5_35_5684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013603\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013629\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170167\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013634\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472626\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3068095\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013618\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013604\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170219\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013608\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484464\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916288\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299316\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170175\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170177\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170189\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013636\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484465\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013623\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1013637\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15983\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15983|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=related_link\">",
"      Fenoldopam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5685="Mini nutritional assesment";
var content_f5_35_5685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Mini nutritional assessment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 827px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Malnutrition indicator score: &ge;24 points = well nourished; 17 to 23.5 points = at risk for malnutrition; &lt;17 points = malnourished.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996; 54 (1 Pt 2):S59. Copyright &copy; 1996 International Life Sciences Institute.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5685=[""].join("\n");
var outline_f5_35_5685=null;
var title_f5_35_5686="Ritonavir: Patient drug information";
var content_f5_35_5686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ritonavir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     see \"Ritonavir: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/9/6298?source=see_link\">",
"     see \"Ritonavir: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norvir&reg;;",
"     </li>",
"     <li>",
"      Norvir&reg; SEC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ritonavir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hemophilia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697267",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or are taking a cholesterol-lowering drug, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698467",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your cholesterol checked before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritated pancreas may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix solution with chocolate milk, Ensure&reg;, or Advera&reg;.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake solution well before use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules in the original container in a refrigerator or at room temperature. If stored at room temperature, throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store solution in the original container at room temperature. Keep the cap tightly closed. Throw away when the date on the bottle has been reached.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2732275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets in the original container at room temperature. Keep the cap tightly closed. Throw away when the date on bottle has been reached. If stored outside of the original container, throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11855 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-504D3CBC15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5686=[""].join("\n");
var outline_f5_35_5686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218758\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218759\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025331\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025333\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025332\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025337\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025338\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025340\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025335\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025336\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025341\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025342\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=related_link\">",
"      Ritonavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/9/6298?source=related_link\">",
"      Ritonavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5687="Microbiology of nontuberculous mycobacteria";
var content_f5_35_5687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Microbiology of nontuberculous mycobacteria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5687/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5687/contributors\">",
"     David E Griffith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5687/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5687/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/35/5687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacterial species other than M. tuberculosis and M. leprae are generally free-living organisms that are ubiquitous in the environment. They have been recovered from water, soil, domestic and wild animals, milk, and food [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. As the incidence of tuberculosis (TB) declined in areas of the world where socioeconomic conditions were rapidly advancing, the frequency of isolating nontuberculous mycobacteria (NTM) began to increase, and their relevance to human disease became apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1959, Runyon proposed the first classification system for these organisms that divided human isolates of NTM into four groups on the basis of growth rates, colony morphology, and pigmentation in the presence and absence of light (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/6\">",
"     6",
"    </a>",
"    ]. Though now outdated, this classification allowed mycobacterial laboratories to more readily identify individual species of NTM, resulting in clearer characterization of distinct diseases or syndromes associated with these organisms.",
"   </p>",
"   <p>",
"    With the availability of 16S ribosomal DNA sequencing and high-performance liquid chromatography (HPLC), and polymerase chain reaction-restriction length polymorphism analysis (PRA), the number of new species of NTM has risen dramatically with the naming of species such as M. genavense, M. interjectum, M. triplex, M. celatum, and M. lentiflavum. Over 100 species have been recognized in the genus Mycobacterium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology of NTM will be reviewed here. Other issues related to NTM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=see_link\">",
"     \"Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=see_link\">",
"     \"Pathogenesis of nontuberculous mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"     \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within the genus Mycobacterium, four groups of human pathogens can be delineated on the basis of microbiologic, clinical, and epidemiologic characteristics (",
"    <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The M. tuberculosis complex",
"     </li>",
"     <li>",
"      M. leprae",
"     </li>",
"     <li>",
"      Slowly growing nontuberculous mycobacteria",
"     </li>",
"     <li>",
"      Rapidly growing mycobacteria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common nontuberculous species causing human disease in the United States are the slowly growing species of the M. avium complex (MAC) and M. kansasii. Less common human pathogens include the slowly growing species M. marinum, M. xenopi, M. simiae, M. malmoense, and M. ulcerans, and the rapidly growing species M. abscessus, M. fortuitum, and M. chelonae. Certain relatively common laboratory isolates, such as M. gordonae, are important to clinicians because they often are contaminants and uncommonly are true pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=see_link\">",
"     \"Buruli ulcer (Mycobacterium ulcerans infection)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern microbiologic techniques for mycobacteria evolved in the context of isolating M. tuberculosis. Microscopic examination after staining and culture using specific media are the cornerstones of the identification of mycobacteria. All mycobacteria share the characteristic of \"acid-fastness,\" ie, after staining with carbol-fuchsin or auramine-rhodamine, they do not decolorize with acidified alcohol. Thus, the common term acid-fast bacilli (AFB) is essentially synonymous with mycobacteria. Nocardia, the main exception, is weakly or variably acid-fast, but often a modified acid fast stain is necessary to distinguish this characteristic in Nocardia species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specimens may be stained with the Ziehl-Neelsen stain or one of its modifications, such as the Kinyoun stain, and examined by routine light microscopy. However, microscopy is relatively insensitive, since at least 10,000 organisms per milliliter of sputum are required for smear positivity. Thus, other procedures are often performed in order to increase the sensitivity of direct microscopy of clinical specimens.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most laboratories use a fluorochrome stain such as auramine-O or auramine-rhodamine and examine specimens by fluorescence microscopy.",
"     </li>",
"     <li>",
"      Liquid specimens may be centrifuged first and the sediment stained.",
"     </li>",
"     <li>",
"      Experienced microscopists may also detect mycobacteria in Gram stained specimens in which they appear as refractile gram positive or gram neutral rods. Under a 100x oil immersion objective, mycobacteria are slightly bent, often beaded rods 2 to 4 microns in length and 0.2 to 0.5 microns in width.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the presence or absence of mycobacteria in clinical specimens has traditionally required culture, because of the relative insensitivity of direct microscopy. In general, clinical specimens that are normally sterile, such as blood, cerebrospinal fluid, or serous fluids, can be inoculated directly onto media. In comparison, nonsterile specimens, such as sputum or pus, must be chemically decontaminated first in order to eliminate common bacteria and fungi that would overwhelm the culture. However, decontamination procedures may inhibit the growth of mycobacteria, especially NTM, as well.",
"   </p>",
"   <p>",
"    Clinical specimens for mycobacterial cultures should be inoculated onto one or more solid media (eg, Middlebrook 7H11 media",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Lowenstein-Jensen media, the former of which is the preferred medium for NTM) and into a liquid medium such as BACTEC 12B broth or Mycobacteria growth indicator tube [MGIT] broth. Growth of visible colonies on solid media typically requires two to four weeks generally at 35 to 37&ordm;C for slowly growing NTM and 30&ordm;C for rapidly growing NTM and M. marinum. Primary cultures in modern liquid media, such as the radiometric BACTEC system, usually produce results within 10 to 14 days. However, this method is not 100 percent sensitive; as a result, it supplements but does not replace traditional solid media.",
"   </p>",
"   <p>",
"    Traditional methods of speciating mycobacterial isolates were based upon growth characteristics on solid media and subsequent biochemical tests, requiring additional weeks for subcultures. These time-consuming methods are being replaced with more rapid techniques. These techniques include specific nucleic acid probes, which are now available for the most common isolates (M. tuberculosis complex, M. kansasii, M. avium complex, and M. gordonae), and HPLC, which evaluates mycolic acid patterns in AFB smear-positive sputum samples (M. tuberculosis and MAC) and in primary positive cultures and permits identification of some species within hours. HPLC is, however, not sufficient for definitive species identification for many NTM species, including the rapidly growing mycobacteria.",
"   </p>",
"   <p>",
"    Other newer techniques include 16S ribosomal DNA sequencing and polymerase chain reaction-restriction length polymorphism analysis (PRA) also allow NTM to be identified and speciated more reliably and rapidly from clinical specimens. Cost considerations limit widespread adoption of these techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional methods of testing mycobacteria for susceptibility to antituberculosis drugs were developed for M. tuberculosis but may not apply directly to NTM (see below). The most common, called the proportion method, compares growth in media containing a specified concentration of the drug to growth in the absence of the drug. Colony growth on drug-containing media that exceeds one percent of the number of colonies growing in the absence of the drug indicates resistance to that drug. For liquid media, such as the BACTEC system, this procedure has been modified to yield comparable results.",
"   </p>",
"   <p>",
"    Only one \"critical concentration\" of drug is usually tested in contrast to other common bacteria where many drug concentrations are tested, yielding the familiar \"MIC\" or minimum inhibitory concentration. For rapidly growing mycobacteria, a broth microdilution system similar to that used for bacterial species is the preferred method. The broth microdilution method for susceptibility testing is also preferred for M. marinum, M. kansasii and Mycobacterium avium complex (MAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM AVIUM COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The M. avium complex (MAC) includes M. avium, M. intracellulare, M. chimaera, and M. colombiense. M. scrofulaceum was once grouped with these organisms as the \"MAIS complex\" (M. avium-intracellulare-scrofulaceum) but this antedated modern diagnostic methods which readily separate M. scrofulaceum. While M. avium and M. intracellulare are also separate species, their separation has no clinical value for individual patients and is generally not performed.",
"   </p>",
"   <p>",
"    MAC are slowly growing organisms that are readily detected by acid fast smear and culture techniques. The organisms grow well in standard media such as BACTEC 12B broth and on Middlebrook 7H10 and 7H11 agar. In broth, the organisms do not show clustering or \"cording,\" and, on agar, MAC typically produces small, flat, translucent, smooth colonies that occasionally exhibit a pale yellow color. These colony morphologies differ from M. tuberculosis, which typically shows cording in broth and appears as rough, buff colored colonies on agar.",
"   </p>",
"   <p>",
"    Highly accurate nucleic acid probes (Accuprobe, GenProbe, Inc) are commercially available that can identify MAC isolates within one day after recognizable growth is evident, a technique currently used by most reference laboratories. These organisms can also be rapidly identified by their mycolic acid patterns from the same samples by HPLC, although the capital investment required limits this methodology to high volume laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing of MAC is difficult and controversial compared with M. tuberculosis. The single critical concentrations of drugs used for the testing of M. tuberculosis were initially chosen to separate treated from untreated strains and provided reasonable predictive values of clinical susceptibility and resistance for tuberculosis. These same values have not been useful for MAC, since almost all isolates are resistant to these single concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/9\">",
"     9",
"    </a>",
"    ]. Despite these in vitro results, combination drug therapy is often clinically and microbiologically successful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/10\">",
"     10",
"    </a>",
"    ]. The one exception is susceptibility testing to the macrolides for which the MICs have been shown to correlate clinically with in vivo response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine in vitro susceptibility testing of MAC is not performed by most laboratories. An exception is testing for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance, which can be detected by a mutation in the 23S ribosomal macrolide binding site [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/12\">",
"     12",
"    </a>",
"    ]. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) and the 2007 American Thoracic Society",
"    <span class=\"nowrap\">",
"     (ATS)/Infectious",
"    </span>",
"    Diseases Society of America (IDSA) statement recommendations suggest that macrolide susceptibility testing should be performed for all clinically important MAC isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the broth microdilution method,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    susceptible MAC isolates have an MIC &le;8",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Susceptibility testing against other agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , clofazimine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , is not recommended since in vitro results have no correlation with clinical (in vivo) response. It may be reasonable to test newer quinolones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    especially with macrolide-resistant MAC isolates (CLSI).",
"   </p>",
"   <p>",
"    Recent efforts have focused on the potential usefulness of specific MIC determinations as a tool to guide drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/13\">",
"     13",
"    </a>",
"    ]. Unfortunately, this technique has yet to be assessed in a comparative clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MYCOBACTERIUM KANSASII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike other NTM, M. kansasii has never been found in soil or natural water supplies, but has been recovered consistently from tap water in cities where M. kansasii is endemic [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/14\">",
"     14",
"    </a>",
"    ]. M. kansasii is seen on smear and recovered in culture by techniques designed for M. tuberculosis. It grows readily in the BACTEC broth, as well as on Middlebrook 7H10 agar and Lowenstein-Jensen agar. The organism typically produces rough large colonies that turn bright yellow with exposure to light (photochromogen). A species-specific nucleic acid probe for the identification of M. kansasii is commercially available (Accuprobe, GenProbe, Inc); this assay can be used once growth has occurred in culture.",
"   </p>",
"   <p>",
"    M. kansasii is readily identified by biochemical tests and by HPLC. On acid fast smears, M. kansasii typically appears as a large, long bacillus which has unusual beading when stained with Ziehl-Neelsen or Kinyoun stains. This finding suggests M. kansasii rather than M. tuberculosis.",
"   </p>",
"   <p>",
"    Acceptable susceptibility testing methods include agar proportion and broth micro dilution. Traditional proportion method susceptibilities of M. kansasii, using the single critical concentrations for M. tuberculosis, are most useful for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    . Essentially all untreated of M. kansasii will be susceptible to 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and 5",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    respectively, of these two drugs.",
"   </p>",
"   <p>",
"    Unfortunately, the single critical concentrations of 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    and 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    used to separate treated from untreated strains of M. tuberculosis are not particularly useful for M. kansasii. Thus, resistance to either isoniazid or streptomycin at these concentrations should be ignored and should play no role in decision making about therapy. Almost all isolates are susceptible to 5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of isoniazid or 10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    of streptomycin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ATS/IDSA",
"    </span>",
"    statement on the diagnosis and treatment of NTM recommends testing of M. kansasii isolates only for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    susceptibility initially, with susceptibility to other drugs tested only if the isolate is resistant to rifampin at 1",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/11\">",
"     11",
"    </a>",
"    ]. M. kansasii are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    at all test concentrations in vitro, as are all species of the nontuberculous mycobacteria. Susceptibility testing to secondary agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , quinolones, aminoglycosides) should be performed only if the M. kansasii isolate is resistant in vitro to rifampin (CLSI). Additionally, a proposal has been made to the CLSI to report clarithromycin MICs of M. kansasii because clarithromycin-containing regimens are often useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RAPIDLY GROWING MYCOBACTERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapidly growing mycobacteria (RGM) include numerous species, but the main clinically relevant species are M. fortuitum, M. chelonae, and M. abscessus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/16\">",
"     16",
"    </a>",
"    ]. They are generally considered to be environmental saprophytes which are widely distributed in nature; they have been isolated from soil, dust, natural surface and municipal water, wild and domestic animals, and fish [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. The organisms grow readily on Middlebrook 7H10 or 7H11 agar and BACTEC 12B broth, as well as routine bacteriologic media such as 5 percent sheep blood agar or chocolate agar, within seven days. Temperature requirements may also be important since some strains of M chelonae grow optimally at 30&ordm;C rather than 35 to 37&ordm;C.",
"   </p>",
"   <p>",
"    M. fortuitum is the most common of the RGM encountered in clinical practice or in the clinical microbiology laboratory. The laboratory impression is that these organisms do not always stain well with the Ziehl-Neelsen or Kinyoun method and may not be recognized readily with the fluorochrome method. RGM are also highly susceptible to the NaOH decontamination procedures which are used to remove other bacteria from specimens. Thus, quantitation of the amount of RGM organisms present by smear or culture can be difficult and should be assessed carefully.",
"   </p>",
"   <p>",
"    Separation of M. fortuitum from M. chelonae and M. abscessus can be accomplished in the laboratory if at least two tests (usually iron uptake and nitrate reduction) are used [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/18\">",
"     18",
"    </a>",
"    ]. Separation of M. chelonae and M. abscessus cannot reliably be accomplished with HPLC or commercial DNA probes, but can be accomplished biochemically (utilization of citrate), by drug susceptibility patterns and by polymerase chain reaction-restriction length polymorphism analysis (PRA). The clinical source of the mycobacterial isolate can be an important clue to the identification of the organism. For instance M. abscessus is a common respiratory pathogen while M. chelonae is an exceedingly rare respiratory pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. fortuitum, M. abscessus, and M. chelonae are resistant to all of the antituberculosis drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ), while M. chelonae and M. abscessus are also usually resistant to a number of other oral agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and sulfonamides) used to treat M. fortuitum [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/19\">",
"     19",
"    </a>",
"    ]. All isolates of M. abscessus and M. chelonae, and approximately 80 percent of isolates of M. fortuitum are susceptible in vitro to the macrolide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/20\">",
"     20",
"    </a>",
"    ]. Because of these resistance patterns, routine susceptibility testing to antituberculosis drugs is not recommended for RGM [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/7,11,21\">",
"     7,11,21",
"    </a>",
"    ]. Isolates should be tested against selected antibacterial agents such as clarithromycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , fluoroquinolones, doxycycline (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    (tobramycin is the preferred aminoglycoside for M. chelonae, which is usually resistant in vitro to amikacin) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5687/abstract/11,21\">",
"     11,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended susceptibility testing method for RGM is the broth microdilution technique with MIC determinations and resistance breakpoints similar to those used for other bacterial species.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFREQUENT OR DIFFICULT TO CULTURE NTM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of infrequently encountered species have been recently described or have become clinically more important. These include M. xenopi, M. simiae, M. malmoense, M. genavense, M. haemophilum, and M. smegmatis. Susceptibility testing is generally performed on these species, but what drugs to test and how useful they are is just beginning to be understood. Some species require special conditions for growth, such as M. haemophilum (iron or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    supplementation, 30&ordm;C incubation) and M. genavense (BACTEC 12B or 13A broth with six weeks incubation). The recommended susceptibility methods for M. marinum include agar proportion, and microdilution broth MIC at 30&ordm;C. However, Routine MICs are not recommended because all untreated strains have the same susceptibility pattern. Drug testing is necessary only in special circumstances such as therapy failure (CLSI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216947832\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the availability of 16S ribosomal DNA sequencing and high-performance liquid chromatography (HPLC), and polymerase chain reaction-restriction length polymorphism analysis (PRA), the number of new species of nontuberculous mycobacteria (NTM) has risen dramatically with the naming of species, such as M. genavense, M. interjectum, M. triplex, M. celatum, and M. lentiflavum. Approximately 150 species have been recognized in the genus Mycobacterium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Within the genus Mycobacterium, four groups of human pathogens can be delineated on the basis of microbiologic, clinical, and epidemiologic characteristics (",
"      <a class=\"graphic graphic_table graphicRef61936 \" href=\"UTD.htm?3/0/3085\">",
"       table 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The M. tuberculosis complex",
"     </li>",
"     <li>",
"      M. leprae",
"     </li>",
"     <li>",
"      Slowly growing nontuberculous mycobacteria",
"     </li>",
"     <li>",
"      Rapidly growing mycobacteria (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common nontuberculous species causing human disease in the United States are the slowly growing species of the M. avium complex (MAC) and M. kansasii and the rapidly growing species M. abscessus. Less common human pathogens include the slowly growing species M. marinum, M. xenopi, M. simiae, M. malmoense, and M. ulcerans, and the rapidly growing species M. massiliense, M. fortuitum, and M. chelonae. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microscopic examination after staining and culture using specific media are the cornerstones of the identification of mycobacteria. All mycobacteria share the characteristic of \"acid-fastness,\" ie, after staining with carbol-fuchsin or auramine-rhodamine, they do not decolorize with acidified alcohol. Confirmation of the presence or absence of mycobacteria in clinical specimens has traditionally required culture, because of the relative insensitivity of direct microscopy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Highly accurate nucleic acid probes are commercially available that can identify MAC isolates within one day after recognizable growth is evident, a technique currently used by most reference laboratories. A similar nucleic acid probe is also available for the identification of M. kansasii. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Mycobacterium avium complex'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Mycobacterium kansasii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine in vitro susceptibility testing of MAC is not performed by most laboratories. An exception is testing for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      resistance, which can be detected by a mutation in the 23S ribosomal macrolide binding site. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) and the 2007 American Thoracic Society",
"      <span class=\"nowrap\">",
"       (ATS)/Infectious",
"      </span>",
"      Diseases Society of America (IDSA) Statement recommendations suggest that macrolide susceptibility testing should be performed for all clinically important MAC isolates. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The 2007",
"      <span class=\"nowrap\">",
"       ATS/IDSA",
"      </span>",
"      statement on the diagnosis and treatment of NTM recommends testing of M. kansasii isolates only for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      susceptibility initially, with susceptibility to other drugs tested only if the isolate is resistant to rifampin at 1",
"      <span class=\"nowrap\">",
"       microgram/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mycobacterium kansasii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapidly growing mycobacterial isolates should be tested against selected antibacterial agents, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"       cefoxitin",
"      </a>",
"      , imipenem,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      , fluoroquinolones,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (tobramycin is the preferred aminoglycoside for M. chelonae, which is usually resistant in vitro to amikacin). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Susceptibility testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/1\">",
"      Wolinsky E, Rynearson TK. Mycobacteria in soil and their relation to disease-associated strains. Am Rev Respir Dis 1968; 97:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/2\">",
"      Chapman JS. The ecology of the atypicalmycobacteria. Arch Environ Health 1971; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/3\">",
"      Goslee S, Wolinsky E. Water as a source of potentially pathogenic mycobacteria. Am Rev Respir Dis 1976; 113:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/4\">",
"      Gruft H, Falkinham JO 3rd, Parker BC. Recent experience in the epidemiology of disease caused by atypical mycobacteria. Rev Infect Dis 1981; 3:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/5\">",
"      Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 1979; 119:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/6\">",
"      RUNYON EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am 1959; 43:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/7\">",
"      Brown-Elliott BA, Griffith DE, Wallace RJ Jr. Newly described or emerging human species of nontuberculous mycobacteria. Infect Dis Clin North Am 2002; 16:187.",
"     </a>",
"    </li>",
"    <li>",
"     NCCLS (formerly National Committee for Clinical Laboratory Standards) Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard (M24-A) 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/9\">",
"      Woodley CL, Kilburn JO. In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. Am Rev Respir Dis 1982; 126:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/10\">",
"      Ahn CH, Ahn SS, Anderson RA, et al. A four-drug regimen for initial treatment of cavitary disease caused by Mycobacterium avium complex. Am Rev Respir Dis 1986; 134:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/11\">",
"      Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/12\">",
"      Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/13\">",
"      Heifets LB, Iseman MD. Individualized therapy versus standard regimens in the treatment of Mycobacterium avium infections. Am Rev Respir Dis 1991; 144:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/14\">",
"      Steadham JE. High-catalase strains of Mycobacterium kansasii isolated from water in Texas. J Clin Microbiol 1980; 11:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/15\">",
"      Good RC, Silcox VA, Kilburn JO, et al. Identification and drug susceptibility test results from mycobacterial spp. Clin Microbiol Newsletter 1985; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/16\">",
"      Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev 2002; 15:716.",
"     </a>",
"    </li>",
"    <li>",
"     Chapman J. The Atypical Mycobacteria, Plenum Publishing, New York 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/18\">",
"      Silcox VA, Good RC, Floyd MM. Identification of clinically significant Mycobacterium fortuitum complex isolates. J Clin Microbiol 1981; 14:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/19\">",
"      Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/20\">",
"      Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5687/abstract/21\">",
"      Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis 1990; 142:940.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5343 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.124.11.8-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5687=[""].join("\n");
var outline_f5_35_5687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H216947832\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MYCOBACTERIUM AVIUM COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MYCOBACTERIUM KANSASII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RAPIDLY GROWING MYCOBACTERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFREQUENT OR DIFFICULT TO CULTURE NTM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H216947832\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5343|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/0/3085\" title=\"table 1\">",
"      Mycobacteria classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39033?source=related_link\">",
"      Buruli ulcer (Mycobacterium ulcerans infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11045?source=related_link\">",
"      Diagnosis of nontuberculous mycobacterial infections of the lungs in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25288?source=related_link\">",
"      Pathogenesis of nontuberculous mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5688="Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis";
var content_f5_35_5688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classic Kaposi sarcoma: Epidemiology, risk factors, pathology, and molecular pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Susan E Krown, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Jasmeet Chadha Singh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     June K Robinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma (KS) is an angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8), also known as Kaposi sarcoma-associated Herpes virus (KSHV), for its development [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The disease is named for Moritz Kaposi, a Hungarian dermatologist on the faculty of the University of Vienna, who first described the entity in 1872 as \"idiopathic multiple pigmented sarcoma of the skin\" [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KS is classified into four types based upon the clinical circumstances in which it develops: classic (the type originally described by Kaposi, which typically presents in middle or old age), endemic (several forms described in Sub-Saharan indigenous Africans prior to the AIDS epidemic), iatrogenic (a type associated with immunosuppressive drug therapy, typically seen in renal allograft recipients), and AIDS-associated (epidemic KS). The different epidemiologic and clinical aspects of these four types are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76370 \" href=\"UTD.htm?18/16/18700\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic review will focus on the epidemiology, risk factors, pathology, and molecular pathogenesis of classic KS (CKS). The clinical presentation, diagnosis, staging, and treatment of CKS is discussed elsewhere as is AIDS-related KS, and iatrogenic KS developing in the setting of immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=see_link\">",
"     \"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link&amp;anchor=H10#H10\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Kaposi's sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic Kaposi sarcoma (CKS) affects men more often than women; the reported male to female ratio is approximately 3:1 [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Although cases have been described around the world, including South America [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/8\">",
"     8",
"    </a>",
"    ] and Asia [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/9\">",
"     9",
"    </a>",
"    ], the disease is most often diagnosed in individuals from the Mediterranean basin and Central and Eastern Europe [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/10-12\">",
"     10-12",
"    </a>",
"    ] or their descendants [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/5,13-15\">",
"     5,13-15",
"    </a>",
"    ]. The highest incidence rates in Europe are in two Mediterranean Italian islands, Sardinia and Sicily [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The geographic distribution of CKS corresponds to regional differences in the prevalence of HHV-8 infection [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/11\">",
"     11",
"    </a>",
"    ]. A discussion of potential routes of HHV-8 spread is beyond the scope of this review; however, an excellent summary is available that identifies salivary shedding together with unidentified sociocultural practices that promote saliva passage as the likely route of infection in children in endemic, high prevalence areas [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/17\">",
"     17",
"    </a>",
"    ]. The global regional and gender-specific seroprevalence of HHV-8 infection and aspects of viral transmission are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CKS typically first presents in men (and women, although less often) in their 60s and 70s but has been described in patients in their teens and 20s [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Only 4 to 8 percent of cases develop in individuals younger than age 50 [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HHV-8 infection is required for the development of Classic Kaposi sarcoma (CKS), but not all infected persons develop the disease. In the Mediterranean area, for example, CKS develops annually in only 0.03 percent of HHV-8-infected men and only 0.01 to 0.02 percent of HHV-8-infected women over age 50 [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/20\">",
"     20",
"    </a>",
"    ]. This implies the existence of cofactors that influence the risk of CKS after infection with HHV-8.",
"   </p>",
"   <p>",
"    Interpretation of most studies evaluating potential risk factors for CKS in persons infected with HHV-8 is limited because comparisons were made with control groups whose HHV-8 infection status was unknown. This limitation was overcome by a series of studies performed in Italy in which case patients with CKS were compared with HHV-8-infected persons (ie, those with antibodies to HHV-8) but without KS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. The following sections describe those factors that have been found to be associated with an elevated risk of CKS among infected persons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anti-HHV-8 antibodies and viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comparison of age- and sex-matched HHV-8-infected Italians with and without CKS showed that HHV-8 DNA detection in peripheral blood mononuclear cells (PBMCs) and high HHV-8 lytic and latent antibody titers were significantly associated with the development of CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More recently, it has been suggested that a certain subtype of HHV-8, strain A, may be associated with higher blood viral loads and more aggressive disease behavior than strain C, which was associated with slowly progressive disease [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inherited variations in immunomodulating genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;KS lesions are characterized, in part, by the presence of proinflammatory cytokines and growth factors that are thought to regulate HHV-8 replication and possibly CKS pathogenesis. The influence of inherited variations in genes that modulate cytokine expression on the development of CKS was addressed in a study of 28 common genetic variants of 14 immunomodulatory genes using genomic DNA from HHV-8-infected Italians with and without CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/21\">",
"     21",
"    </a>",
"    ]. The risk of CKS was associated with specific haplotypes of the interleukin-8 receptor-beta (IL8RB) and IL13 genes. Although it is not clear how these genes cooperate to promote CKS pathogenesis, or whether either or both work directly or indirectly to promote CKS pathogenesis, the findings suggest that genetically determined differences in cytokine expression may influence CKS risk.",
"   </p>",
"   <p>",
"    In addition to these observations, others have found that among HHV-8-infected Italians without CKS, high HHV-8 lytic antibody titers, which may be a marker of lytic reactivation, were associated with a common promoter variant in IL6, and a specific haplotype of IL4, and a high latent HHV-8 antibody titer was associated with a specific haplotype of the IL12 subunit A (IL12A) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/23\">",
"     23",
"    </a>",
"    ]. These findings suggest that host genetic factors may affect the risk of CKS at least in part by influencing the ability to develop antibodies to HHV-8 and ultimately, control HHV-8 infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppression, either iatrogenic (ie, in allograft recipients) or acquired (ie, in the setting of HIV infection) is well described as a risk factor for KS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link&amp;anchor=H10#H10\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Kaposi's sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of immunosuppression in CKS is less well defined, and there is no evidence for overt immunosuppression in most cases. However, there is evidence that more subtle degrees of immune suppression may be present in people with CKS. The following represents the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a previously described Italian study, patients with CKS were found to have a significantly lower total lymphocyte count than HHV-8-seropositive individuals without KS, although the mean absolute values for both total lymphocytes and the CD4 and CD8 T-lymphocyte subsets were within the normal range in affected patients [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22\">",
"       22",
"      </a>",
"      ]. In particular, a lymphocyte count below the median among younger individuals (age &lt;70) was strongly associated with an increased risk of CKS (odds ratio [OR] 8.0).",
"     </li>",
"     <li>",
"      Significantly lower total lymphocyte counts and CD4+ T cells were observed in a group of 91 Greek patients with CKS compared to age- and sex-matched controls without CKS (although their HHV-8 infection status was not specified) [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/28\">",
"       28",
"      </a>",
"      ]. As in the previously cited study, mean values for all lymphocyte parameters were within the normal range in patients with CKS.",
"     </li>",
"     <li>",
"      A gradual but significant decrease in the number of total and B-lymphocytes has been linked to progression of CKS from its early stages to more advanced disease [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased risk of CKS has been reported among individuals with a history of topical corticosteroid use (OR: 2.73, 95% CI = 1.35 to 5.51) [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"       24",
"      </a>",
"      ], suggesting that local perturbations in cutaneous immune function may be an important predisposing factor for CKS.",
"     </li>",
"     <li>",
"      There are conflicting data as to the risk of CKS among patients taking oral corticosteroids, with some studies supporting an association [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/26\">",
"       26",
"      </a>",
"      ] and others not [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increased incidence of CKS with advancing age, despite likely infection with HHV-8 early in life, may be a result of age-related immunosenescence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immune activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although immunosuppression has been most consistently associated with the development of CKS, some evidence also supports a possible pathogenetic role for immune activation. One study found increased levels of the immune activation markers, neopterin and beta2-microglobulin, in the serum of patients with CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/9,20\">",
"     9,20",
"    </a>",
"    ]. A link between immune system activation and CKS is also suggested by the association of CKS with a history of asthma and allergy (the latter in men, but not in women) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis for the higher incidence of CKS among men than women is not well understood, but it appears not to be a consequence of significantly higher HHV-8 seroprevalence among men. It has been hypothesized (but not proven) that CKS risk is related to differences in how men and women manage persistent virus over time [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/25\">",
"     25",
"    </a>",
"    ]. This is perhaps a result of a differential action of sex steroids on the immune system to modify antigen presentation, lymphocyte activation, cytokine and immune cell regulation, and the expression of disease resistance genes including Fc Rs and the IgG superfamily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Association with other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on associations with other malignancies, either before or following a diagnosis of CKS, as evidenced by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A strong association between CKS and lymphohematopoietic malignancies was initially suggested by a single-institution US study that described nine cases (four non-Hodgkin's lymphoma, three Hodgkin lymphoma, one multiple myeloma, and one leukemia) diagnosed before, concurrent with, or subsequent to CKS in 72 patients [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/30\">",
"       30",
"      </a>",
"      ]. This corresponded to a 20-fold increase over the number of expected cases in the control population [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similarly, a study of 68 patients from the United Kingdom (UK) also suggested an increased rate of non-Hodgkin's lymphoma subsequent to a diagnosis of CKS, but this conclusion was based on only three lymphoma cases [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study reported six cancer cases, five of which involved the lymphohematopoietic system, among 66 CKS patients presenting to a hospital in Athens, Greece [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/32\">",
"       32",
"      </a>",
"      ]. Three of the cancers were diagnosed concurrently with, one preceded, and two were diagnosed subsequent to the diagnosis of CKS; no attempt was made to correlate cancer incidence with that of a control population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of the subsequent larger population-based studies from the US (492 patients), Italy (201 patients) and a Nordic cohort (741 patients) failed to document an excess risk of cancer overall, or of lymphomas specifically following the diagnosis of CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. However, an Israeli population-based study that investigated CKS as a second primary malignancy did find an increased incidence following a prior diagnosis of non-Hodgkin's lymphoma (OR=5.3), Hodgkin lymphoma (OR=7.5), leukemia (OR=5.3), especially chronic leukemia (OR=10), and breast cancer (OR=2.2) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/36\">",
"     36",
"    </a>",
"    ]. The risk was particularly high among immigrants to Israel from the former Soviet Union (OR=9.4) and Poland (OR=7) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/36\">",
"     36",
"    </a>",
"    ]. It is possible that the increased risk of CKS following a prior cancer diagnosis was related to immunosuppression from cancer treatment in a susceptible, HHV-8-infected immigrant population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have described significantly lower hemoglobin and hematocrit values among patients with CKS as compared to controls without the disease [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22,28\">",
"     22,28",
"    </a>",
"    ], although absolute differences were quite modest and mean values were all within the normal range. The control population in one of the reports consisted of patients with HHV-8 infection without CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22\">",
"     22",
"    </a>",
"    ]. The biological significance of lower red blood cell values and their etiologic role in CKS development, if any, is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors related to skin hygiene or skin disease may influence the development of CKS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, infrequent bathing or showering was associated with a moderately increased risk of CKS [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following up on Ziegler's hypothesis that endemic, African KS is related to localized immune deficiency in the lower extremities that results from chronic exposure of the skin to volcanic soil [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/37\">",
"       37",
"      </a>",
"      ], one study found that the risk of CKS was twofold higher among people born near Mount Vesuvius than among people born in neighboring areas [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report has linked luvisol soils (which are high in iron and alumino-silicates) to the risk of CKS [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Yet another study has suggested that differences in the geographic distribution of certain bloodsucking insects (\"promoter arthropods\") that cause local inflammatory responses may account for variations in the incidence of CKS and HHV-8 infection [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consistent finding is that the risk for CKS is significantly lower among cigarette smokers, particularly those with more intensive (more packs per day) and more cumulative (more pack-years) history of tobacco abuse [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24,26,41\">",
"     24,26,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 141 Italian patients with CKS and 192 HHV-8-seropositive age-matched controls, CKS risk decreased approximately 20 percent (OR=0.81, 95% CI = 0.74 to 0.89) for each 10 pack-years of smoking and was decreased sevenfold (OR=0.14, 95% CI = 0.07 to 0.30) among men with a greater than 40 pack-year history [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An even more dramatic protective effect was noted in a later study from these same investigators that included 142 Sicilian CKS cases and 123 HHV-8-seropositive controls [",
"      <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/26\">",
"       26",
"      </a>",
"      ]. Current cigarette smoking was associated with an 80 percent reduction in CKS among males (OR 0.20, 95% CI 0.06-0.67).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are consistent with other studies in HIV-infected men in the US, which show a statistically significant reduction in KS risk among smokers [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/41\">",
"     41",
"    </a>",
"    ], and they are supported by reports of a lower risk of other smoking-related diseases, including lung cancer, among people with CKS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/13,30,36\">",
"     13,30,36",
"    </a>",
"    ]. It has been suggested that the protective effect of smoking may be mediated by a decrease in the production of inflammatory cytokines [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24,41\">",
"     24,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another Italian case-control study documented a 3.65-fold increased risk of CKS among patients with chronic edema of the lower extremities, and among those with diabetes mellitus (OR 4.73) [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/26\">",
"     26",
"    </a>",
"    ]. It is postulated that local factors related to vascular insufficiency might predispose to KS and in particular, to its preferential appearance on the lower extremities.",
"   </p>",
"   <p>",
"    In contrast, no associations have been found between CKS risk and alcohol consumption, number of lifetime sexual partners, household crowding or birth order, or with detection of Epstein-Barr virus (EBV) DNA in PBMCs [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22,24\">",
"     22,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microscopic features of all four different types of Kaposi sarcoma (KS) do not differ. All forms show evidence of angiogenesis, inflammation and spindle cell proliferation.",
"   </p>",
"   <p>",
"    Three main pathological stages have been described in the progression of the lesions of KS [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In the \"patch\" stage, thin-walled vascular spaces are visible in the upper dermis with a sparse mononuclear cell infiltrate of lymphocytes, plasma cells, and macrophages. In the \"plaque\" stage, the vascular spaces increase in number, the inflammatory infiltrate is more dense, and spindle-cell bundles accumulate around the areas of angioproliferation. In the \"nodular\" stage, the tumor is more solid and there are well-defined nodules which consist of large fascicles of spindle-shaped endothelial cells with fewer and more compact vascular slits. The mononuclear cell infiltrate is no longer prominent and few extravasated erythrocytes and macrophages are present between spindle cells [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lining cells of the clearly developed vascular structures are positive for vascular markers (such as factor VIII), while the spindle cells consistently stain for CD34 and commonly CD31 but are factor VIII negative.",
"   </p>",
"   <p>",
"    If needed, polymerase chain reaction can be performed of the skin lesions to detect amplified HHV-8 DNA sequences, and immunohistochemical staining of biopsy specimens can also be performed to detect the presence of HHV-8 latent antigen within the spindle cells, thus confirming the diagnosis [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MOLECULAR PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complex mechanisms by which HHV-8 infects and transforms human endothelial cells, which form the neoplastic spindle-cell component of the Kaposi sarcoma (KS) lesion, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=see_link&amp;anchor=H2#H2\">",
"     \"Virology, epidemiology, and transmission of human herpesvirus 8 infection\", section on 'Virology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In brief, several viral gene products of HHV-8 affect both cell cycle regulation and the control of apoptosis, and segments of the HHV-8 genome contain viral oncogenes that are important in the pathogenesis of tumor formation. Most of the spindle cells within the KS lesions show latent infection with HHV-8, although a small proportion of cells express lytic cycle genes. The limited number of viral genes expressed during latency are those which permit the virus to replicate within the host cell as an episome while disrupting the function of tumor suppressor genes and avoiding recognition by the host immune system. On the other hand, viral genes expressed during the lytic cycle may be particularly important in increased expression of growth factors, such as vascular endothelial growth factor (VEGF), that stimulate angiogenesis and activate growth regulatory pathways, such as the PI3-kinase pathway, that lead to dysregulated cell growth [",
"    <a class=\"abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not known whether the presence of peripheral vascular disease (with resultant tissue hypoxia and local elaboration of angiogenic factors) accounts for the frequent development of KS lesions on the lower extremities of the elderly patients who are at greatest risk for classic Kaposi sarcoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=see_link\">",
"       \"Patient information: Kaposi sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma (KS) is an angioproliferative disorder that requires infection with human herpes virus 8 (HHV-8), also known as Kaposi sarcoma-associated Herpes virus (KSHV), for its development. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Several viral gene products of HHV-8 affect both cell cycle regulation and the control of apoptosis, and segments of the HHV-8 genome contain viral oncogenes that are important in the pathogenesis of tumor formation. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Molecular pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    KS is classified into four types based upon the clinical circumstances in which it develops: classic, endemic, iatrogenic, and AIDS-associated. The different epidemiologic and clinical aspects of these four types are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef76370 \" href=\"UTD.htm?18/16/18700\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Classic KS is most often diagnosed in men from the Mediterranean basin and Central and Eastern Europe or their descendants. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    HHV-8 infection is required for the development of CKS, but not all infected persons develop the disease. Immunosuppression is a well described risk factor for KS. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Three main pathological stages have been described in the progression of the lesions of KS: the patch stage, plaque stage, and nodular stage (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Pathology'",
"    </a>",
"    above).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/1\">",
"      Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med 1996; 335:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/2\">",
"      Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996; 2:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/3\">",
"      Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/4\">",
"      Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. [English translation from Archiv F&uuml;r Dermatolgie Und Syphillis 1872; 4:265-273]. CA Cancer J Clin 1982; 32:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/5\">",
"      Dal Maso L, Polesel J, Ascoli V, et al. Classic Kaposi's sarcoma in Italy, 1985-1998. Br J Cancer 2005; 92:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/6\">",
"      Kaldor JM, Coates M, Vettom L, Taylor R. Epidemiological characteristics of Kaposi's sarcoma prior to the AIDS epidemic. Br J Cancer 1994; 70:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/7\">",
"      Hiatt KM, Nelson AM, Lichy JH, Fanburg-Smith JC. Classic Kaposi Sarcoma in the United States over the last two decades: a clinicopathologic and molecular study of 438 non-HIV-related Kaposi Sarcoma patients with comparison to HIV-related Kaposi Sarcoma. Mod Pathol 2008; 21:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/8\">",
"      Mohanna S, Ferrufino JC, Sanchez J, et al. Epidemiological and clinical characteristics of classic Kaposi's sarcoma in Peru. J Am Acad Dermatol 2005; 53:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/9\">",
"      Jang HS, Cha JH, Oh CK, Kwon KS. A case of classic Kaposi's sarcoma with multiple organ involvement. J Dermatol 2000; 27:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/10\">",
"      Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi's sarcoma in Jews living in Israel, 1961-1989: a population-based incidence study. AIDS 1998; 12:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/11\">",
"      Angeloni A, Heston L, Uccini S, et al. High prevalence of antibodies to human herpesvirus 8 in relatives of patients with classic Kaposi's sarcoma from Sardinia. J Infect Dis 1998; 177:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/12\">",
"      Cattani P, Cerimele F, Porta D, et al. Age-specific seroprevalence of Human Herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect 2003; 9:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/13\">",
"      Dictor M, Attewell R. Epidemiology of Kaposi's sarcoma in Sweden prior to the acquired immunodeficiency syndrome. Int J Cancer 1988; 42:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/14\">",
"      Hjalgrim H, Melbye M, Lecker S, et al. Epidemiology of classic Kaposi's sarcoma in Denmark between 1970 and 1992. Cancer 1996; 77:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/15\">",
"      Touloumi G, Kaklamanis L, Potouridou I, et al. The epidemiologic profile of Kaposi's sarcoma in Greece prior to and during the AIDS era. Int J Cancer 1997; 70:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/16\">",
"      Di Lorenzo G. Update on classic Kaposi sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol 2008; 68:242.",
"     </a>",
"    </li>",
"    <li>",
"     Martin JN. Epidemiology of Kaposi's sarcoma-associated herpesvirus infection. In: Viral and Immunological Malignancies, PA Volberding and J Palefsky (Ed), BC Decker Inc, Hamilton, Ontario 2006. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/18\">",
"      Potouridou I, Katsambas A, Pantazi V, et al. Classic Kaposi's sarcoma in two young heterosexual men. J Eur Acad Dermatol Venereol 1998; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/19\">",
"      Landau HJ, Poiesz BJ, Dube S, et al. Classic Kaposi's sarcoma associated with human herpesvirus 8 infection in a 13-year-old male: a case report. Clin Cancer Res 2001; 7:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/20\">",
"      Vitale F, Briffa DV, Whitby D, et al. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer 2001; 91:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/21\">",
"      Brown EE, Fallin D, Ruczinski I, et al. Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev 2006; 15:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/22\">",
"      Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/23\">",
"      Brown EE, Fallin MD, Goedert JJ, et al. Host immunogenetics and control of human herpesvirus-8 infection. J Infect Dis 2006; 193:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/24\">",
"      Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. J Natl Cancer Inst 2002; 94:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/25\">",
"      Brown EE, Fallin MD, Goedert JJ, et al. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Cancer Epidemiol Biomarkers Prev 2005; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/26\">",
"      Anderson LA, Lauria C, Romano N, et al. Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily. Cancer Epidemiol Biomarkers Prev 2008; 17:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/27\">",
"      Mancuso R, Biffi R, Valli M, et al. HHV8 a subtype is associated with rapidly evolving classic Kaposi's sarcoma. J Med Virol 2008; 80:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/28\">",
"      Touloumi G, Hatzakis A, Potouridou I, et al. The role of immunosuppression and immune-activation in classic Kaposi's sarcoma. Int J Cancer 1999; 82:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/29\">",
"      Stratigos AJ, Malanos D, Touloumi G, et al. Association of clinical progression in classic Kaposi's sarcoma with reduction of peripheral B lymphocytes and partial increase in serum immune activation markers. Arch Dermatol 2005; 141:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/30\">",
"      Safai B, Mik&eacute; V, Giraldo G, et al. Association of Kaposi's sarcoma with second primary malignancies: possible etiopathogenic implications. Cancer 1980; 45:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/31\">",
"      Grulich AE, Beral V, Swerdlow AJ. Kaposi's sarcoma in England and Wales before the AIDS epidemic. Br J Cancer 1992; 66:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/32\">",
"      Stratigos JD, Potouridou I, Katoulis AC, et al. Classic Kaposi's sarcoma in Greece: a clinico-epidemiological profile. Int J Dermatol 1997; 36:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/33\">",
"      Biggar RJ, Curtis RE, Cote TR, et al. Risk of other cancers following Kaposi's sarcoma: relation to acquired immunodeficiency syndrome. Am J Epidemiol 1994; 139:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/34\">",
"      Franceschi S, Arniani S, Balzi D, Geddes M. Survival of classic Kaposi's sarcoma and risk of second cancer. Br J Cancer 1996; 74:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/35\">",
"      Hjalgrim H, Frisch M, Pukkala E, et al. Risk of second cancers in classical Kaposi's sarcoma. Int J Cancer 1997; 73:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/36\">",
"      Iscovich J, Boffetta P, Winkelmann R, Brennan P. Classic Kaposi's sarcoma as a second primary neoplasm. Int J Cancer 1999; 80:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/37\">",
"      Ziegler JL. Endemic Kaposi's sarcoma in Africa and local volcanic soils. Lancet 1993; 342:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/38\">",
"      Montella M, Franceschi S, Geddes M, et al. Classic Kaposi's sarcoma and volcanic soil in southern Italy. Lancet 1996; 347:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/39\">",
"      Pelser C, Dazzi C, Graubard BI, et al. Risk of classic Kaposi sarcoma with residential exposure to volcanic and related soils in Sicily. Ann Epidemiol 2009; 19:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/40\">",
"      Ascoli V, Senis G, Zucchetto A, et al. Distribution of 'promoter' sandflies associated with incidence of classic Kaposi's sarcoma. Med Vet Entomol 2009; 23:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/41\">",
"      Hoover DR, Black C, Jacobson LP, et al. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. Am J Epidemiol 1993; 138:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/42\">",
"      Grayson W, Pantanowitz L. Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008; 3:31.",
"     </a>",
"    </li>",
"    <li>",
"     Kaposi Sarcoma. In: World Health Organization Classification of Tumours. Pathology and genetics. Tumours of soft tissue and bone, Fletcher CDM, Unni KK, Mertens F (Eds), IARC, Lyon, France 2002. p.170.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/44\">",
"      Hbid O, Belloul L, Fajali N, et al. Kaposi's sarcoma in Morocco: a pathological study with immunostaining for human herpesvirus-8 LNA-1. Pathology 2005; 37:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/45\">",
"      Douglas JL, Gustin JK, Dezube B, et al. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. Panminerva Med 2007; 49:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"./classic-kaposi-sarcoma-epidemiology-risk-factors-pathology-and-molecular-pathogenesis/abstract/46\">",
"      Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007; 19:452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7726 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-A7765D755B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5688=[""].join("\n");
var outline_f5_35_5688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anti-HHV-8 antibodies and viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inherited variations in immunomodulating genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immune activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Association with other malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MOLECULAR PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7726\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7726|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/16/18700\" title=\"table 1\">",
"      Epid clin types KS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./classic-kaposi-sarcoma-clinical-features-staging-diagnosis-and-treatment?source=related_link\">",
"      Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./kaposi-sarcoma-the-basics?source=related_link\">",
"      Patient information: Kaposi sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30138?source=related_link\">",
"      Virology, epidemiology, and transmission of human herpesvirus 8 infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5689="Principles of magnetic resonance imaging";
var content_f5_35_5689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of magnetic resonance imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Daniel Chernoff, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Paul Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Nestor L Muller, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/35/5689/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/35/5689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance (MR) imaging is an important tool in the diagnosis and evaluation of diseases, including those affecting the heart, mediastinum, pleura, and chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3910?source=see_link\">",
"     \"Magnetic resonance imaging of the thorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnetic resonance imaging is based on the magnetization properties of atomic nuclei. The ability to induce, detect, and quantify nuclear magnetic resonance (NMR) from bulk materials was developed simultaneously by Bloch and Purcell in 1946 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/2\">",
"     2",
"    </a>",
"    ]. In the early 1970s, Lauterbur and Damadian applied NMR technology to the imaging of living organisms, generating images referred to as zeugmatographs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Subsequent refinements in image acquisition and processing, developed by Sir Peter Mansfield and others, allowed sharper visualization of anatomic detail and broader clinical application of MR imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ]. Lauterbur and Mansfield were awarded the 2003 Nobel Prize in Medicine and Physiology for their contributions to medical imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MR PHYSICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuclei that contain an odd number of protons or neutrons possess a magnetic moment, which describes the strength and direction of a microscopic magnetic field surrounding the nucleus. In the presence of a strong, constant external magnetic field, such as that produced inside an imaging magnet, a small excess fraction of nuclei, on average, align themselves with the magnetic field, producing a macroscopic, measurable magnetic moment (",
"    <a class=\"graphic graphic_figure graphicRef66019 \" href=\"UTD.htm?11/10/11437\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, the interaction between the magnetic moment of the nucleus and the external field causes each nucleus to precess (rotate). Each nucleus precesses at a characteristic (resonant) frequency that is proportional to the strength of the external field. The resonant frequency can be calculated with the Larmor equation:",
"   </p>",
"   <p>",
"    Resonant frequency F = B",
"    <sub>",
"     0",
"    </sub>",
"    x Larmor constant",
"   </p>",
"   <p>",
"    where B",
"    <sub>",
"     0",
"    </sub>",
"    is the magnetic field strength and the Larmor constant is the specific precession frequency of hydrogen at a specified magnetic field strength. For example, a hydrogen nucleus (a proton) precesses at a frequency of 42.57 MHz per Tesla (1 Tesla = 10,000 times the earth's magnetic field strength), while a carbon-13 nucleus precesses at 10.71 MHz per Tesla. Because of the high abundance of hydrogen (1H) nuclei in tissue compared with other atomic nuclei, the proton signal from",
"    <strong>",
"     hydrogen",
"    </strong>",
"    is used in virtually all clinical MR imaging.",
"   </p>",
"   <p>",
"    The fraction of protons aligned with the magnetic field can be perturbed by application of radiofrequency energy at the resonant frequency. The density of protons as well as the rate at which the magnetization returns to equilibrium (relaxation) can then be measured by the radiofrequency signal or echo emitted by the protons (referred to as \"spins\") as they relax. Two forms of relaxation can be measured:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relaxation produced by realignment of the magnetic vector with the external field (spin-lattice or longitudinal relaxation) (",
"      <a class=\"graphic graphic_figure graphicRef53513 graphicRef74502 \" href=\"UTD.htm?6/3/6206\">",
"       figure 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Relaxation produced by loss of phase coherence of spins in a plane perpendicular to the external field (spin-spin or transverse relaxation) (",
"      <a class=\"graphic graphic_figure graphicRef62262 graphicRef78829 \" href=\"UTD.htm?12/19/12606\">",
"       figure 3A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Phase coherence refers to a collection of neighboring spins whose magnetization vectors point in the same direction. Loss of phase coherence occurs when these vectors get out of alignment due to precession of neighboring spins at slightly different velocities, reflecting small, random variations in the local magnetic field. Both longitudinal and transverse relaxation occur at exponential rates, with time constants T1 for longitudinal and T2 for transverse relaxation. These time constants, T1 and T2, in turn depend on the local chemical microenvironment, which varies between tissues.",
"   </p>",
"   <p>",
"    The power of magnetic resonance is that small differences in the microenvironment of different tissues can be detected by pulse sequences designed to emphasize T1, T2, or proton density differences. The presence of multiple magnetic resonance properties of tissue leads to great flexibility in determining tissue contrast, based upon the choice of imaging sequence. This is in contrast to CT, in which only a single property of tissue (electron density) is exploited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MR IMAGING TECHNOLOGY AND PULSE SEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance and signal intensity of tissues in an MR image depend heavily upon the type of imaging technique used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Magnet and coil design",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR imaging requires a large, constant, spatially homogeneous magnetic field. Most clinical MR imaging systems use a superconducting magnet to generate the required magnetic field. The superconducting magnet is composed of windings of special metal alloys (niobium-titanium fibers in an aluminum or copper matrix) cooled by liquid helium, in which electrical current flows without loss of energy. The circular flow of current in the windings induces a constant magnetic field oriented along the bore of the magnet. Additional complex windings are incorporated to allow application of small correction fields, improving field homogeneity. Alternative magnet technologies in clinical use include permanent and resistive magnets, which are generally of lower field strength than superconducting magnets.",
"   </p>",
"   <p>",
"    The majority of clinical MRI systems are based on cylindrical bore magnets, in which the main magnetic field is oriented parallel to the bore. However, so-called open MRI systems have a significant market share, particularly in the USA where open MRI is marketed for large and claustrophobic patients. Most open MRI designs are based on two disc-shaped magnets separated by a gap to accommodate the patient. Although significant engineering challenges have limited the field strength possible with this design, open MRI systems are now available at field strengths up to 1.2 Tesla, close to the 1.5 Tesla that comprises the majority of cylindrical bore MRI systems, but below the 3.0 Tesla that is the current maximum for whole body MRI scanners.",
"   </p>",
"   <p>",
"    Four or more additional windings (or coils) are incorporated in an imaging magnet. Three gradient coils are used to create small linear perturbations of the magnetic field in orthogonal spatial directions. Because the proton precession frequency is linearly related to magnetic field strength, these magnetic gradients can encode the spatial location of protons within the body in the frequency of precession. A radiofrequency (RF) coil is used to provide the bursts of RF energy required to perturb the magnetization of spins within the body. The same RF coil or additional coils are used to receive the echo signal(s) from the body. Specialized RF coils tailored for optimal signal reception are used for different parts of the body.",
"   </p>",
"   <p>",
"    The remainder of the MR imaging system consists of a patient transport system (the \"table\"), RF and magnetic shielding, MR-compatible electrocardiographic and respiratory monitoring systems, and a computer to set up the pulse sequences, perform collection of the echo data, and transform the raw data into images (",
"    <a class=\"graphic graphic_figure graphicRef82585 \" href=\"UTD.htm?13/3/13375\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulse sequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike computed tomography, where tissue contrast depends almost entirely upon electron density, contrast in MR imaging is a complex function of spin density, T1 relaxation, and T2 relaxation. The relative contributions of these parameters to the image vary with the manner in which the tissue is excited. The combination of RF and gradient waveforms used to obtain an image is referred to as a pulse sequence. For thoracic imaging, the most commonly used pulse sequence is called \"spin echo\". For specific applications, such as imaging blood flow or rapid imaging, other types of pulse sequences are employed, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Spin echo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A spin echo (SE) pulse sequence consists of a 90 degree RF pulse to excite the tissue followed by a 180 degree refocusing pulse. The refocusing pulse reverses any dephasing effects that have occurred due to inhomogeneities in the external magnetic field, forming an RF \"echo\" when the spins come back into phase. The elapsed time from the 90 degree pulse to the peak of the echo is called the echo time (TE). The elapsed time between successive 90 degree pulses is called the repetition time (TR). A spin echo sequence with a short TR (eg, 300 to 1000 msec) and a short TE (less than 20 msec) emphasizes the T1 differences between tissues (T1-weighting). A spin-echo sequence with a long TR (3000 to 6000 msec) and a long TE (greater than 80 msec) emphasizes T2 differences (T2-weighting). A long TR sequence with a short TE minimizes the effects of T1 and T2 relaxation and thus reflects proton density, which in turn primarily reflects water content. In order to increase the image contrast, inversion recovery pulses can be added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Gradient echo",
"    </span>",
"    &nbsp;&mdash;&nbsp;A gradient echo (GRE) pulse sequence consists of small angle (typically 20 to 60 degrees) RF pulses applied in rapid succession (TR less than 100 msec). Gradient echo imaging uses a reversal of the magnetic field gradients rather than a 180 degree RF pulse to refocus spins. Image contrast in gradient echo imaging is a complex function of TR, TE, and RF flip angle, and does not generally produce images equal in quality to spin-echo images. Examples of gradient echo sequences include spoiled gradient echo imaging and balanced steady state free precession. There are, however, two major uses of gradient echo imaging in the thorax: fast imaging; and angiographic imaging.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With fast imaging, images are obtained much more rapidly than an equivalent spin-echo sequence. As a result, images can be acquired during a single breath-hold, which improves image quality due to elimination of respiratory motion artifacts. In addition, the temporal pattern of enhancement of tissues following intravenous contrast injection can be assessed by repetitive rapid imaging at one or more locations, a procedure useful in the imaging of tumors.",
"     </li>",
"     <li>",
"      Magnetic resonance angiography (MRA) uses ultrafast acquisition of T1-weighted three-dimensional gradient echo data sets obtained during a breath-hold [",
"      <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/10\">",
"       10",
"      </a>",
"      ]. In this setting, magnetization of stationary tissue within the imaged slice becomes partially \"saturated,\" leading to decreased signal. Blood flowing into the imaged slice, however, will not have experienced repetitive excitations and therefore will have higher signal intensity. The pulse sequence design for contrast-enhanced MRA is based on a three-dimensional Fourier transform gradient recalled echo (GRE) sequence, using rapid radiofrequency pulsing [",
"      <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. The excellent contrast between the bright blood and darker stationary tissue makes gradient echo a useful angiographic sequence for imaging of arterial and venous structures [",
"      <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/13-15\">",
"       13-15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Other sequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to achieve the most rapid imaging possible, various pulse sequences have been developed, all of which have in common the collection of a large amount of data in the form of multiple echoes following each RF excitation. Fast spin echo is an often used modification of the spin echo sequence in which multiple 180 degree refocusing pulses follow a single 90 degree excitation. Fast spin echo can reduce the time required to produce a set of images by a factor equal to the number of refocusing pulses (the echo train length) applied. Fast spin echo is often used in the thorax to allow spin echo imaging with breath-holding. In the most extreme form of rapid imaging, called echo planar imaging, all of the data needed to reconstruct a single two-dimensional slice are acquired after a single RF pulse, in a time as short as 30 to 40 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MAGNETIC RESONANCE CONTRAST AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paramagnetic contrast agents, usually administered intravenously, have assumed a role in MR imaging similar to that played by iodinated contrast agents in CT imaging. Most MR contrast agents in clinical use are chelates of gadolinium. After intravenous injection, these agents initially partition into the vascular space, and then diffuse into the extravascular space. Gadolinium and other paramagnetic substances shorten both T1 and T2 (increase relaxivity), but it is the T1-shortening effect that is clinically relevant at typical tissue concentrations of contrast agent. On T1-weighted images, relatively greater delivery of contrast (increased vascularity) to an area produces an increase in T1-weighted signal intensity over baseline.",
"   </p>",
"   <p>",
"    MR contrast agent safety is discussed below. (See",
"    <a class=\"local\" href=\"#H39\">",
"     'MR contrast agents and renal failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MOTION COMPENSATION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively long time required to collect all the data necessary to reconstruct an image renders MR imaging susceptible to motion artifacts. The types of motion encountered include cardiac, respiratory, flowing blood, swallowing, peristalsis, and gross patient movements. Motion artifacts tend to be most noticeable along the axis along which position is encoded by the phase of the received echo signal. Judicious choice of the phase-encoding axis is helpful in minimizing motion artifact in an area of clinical interest. Most clinical MRI systems now have rapid imaging options which typically can acquire all data in a breathhold, albeit with somewhat reduced spatial resolution",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signal-to-noise ratio. This can obviate the need for motion compensation and has become common for MR imaging of the chest, abdomen and pelvis.",
"   </p>",
"   <p>",
"    More sophisticated techniques are also available to compensate for predictable, repetitive forms of motion, such as cardiac motion, respiratory motion, and blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiac gating",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artifacts created by cardiac motion can be minimized if pulses are synchronized with the cardiac cycle. This requires an electrocardiographic- or pulse-monitoring system. To achieve T1-weighting, TR is usually set to one R-R interval. For T2-weighting (long TR), TR is chosen to be a multiple of an R-R interval. Because of the dominant effects of cardiac motion in the chest, virtually all thoracic imaging is performed with cardiac gating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Respiratory compensation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, the phase encoding gradient is incremented sequentially on successive RF excitations until sufficient data are collected to perform Fourier reconstruction. Respiratory compensation consists of monitoring the respiratory cycle with a flexible belt placed around the patient, and reordering the phase encoding gradients such that adjacent phase encodes occur during similar degrees of inspiration. In the reconstruction process, the data are reordered to make it appear that only one very long respiratory cycle was sampled. This greatly reduces respiratory motion artifact without changing imaging time. This type of motion compensation is therefore used routinely in thoracic imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Flow compensation (gradient moment nulling)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motion occurring between the application of RF excitation and reception of the echo causes changes in the phase of the received signal from the moving tissue, thereby causing misregistration of position along the phase-encoding axis. This artifact can be minimized by altering the gradient waveforms in the slice-selective and frequency axes to produce no net phase-shift for constant velocity motion, a technique called flow-compensation (referring to blood flow) or gradient moment nulling (GMN).",
"   </p>",
"   <p>",
"    GMN produces an increase in signal within blood vessels, and is therefore used routinely in angiographic (gradient echo) sequences. The GMN gradient waveforms increase the minimum achievable TE, which reduces signal-to-noise ratio in short TE (T1- and proton density-weighted images). It is generally less effective than respiratory compensation in reducing breathing motion artifact, and its use in spin-echo imaging is therefore limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPATIAL AND CHEMICAL PRESATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spatial presaturation refers to spatially-selective prepulses applied immediately before the imaging pulse sequence to reduce signal arising from undesired spatial locations. Its main use is in reducing artifact from flowing blood on spin-echo images, but the concept is also used for suppression of respiratory motion artifact. Chemical presaturation (FAT SAT or CHEM SAT) uses a spectrally-selective prepulse to reduce or eliminate signal from fat, taking advantage of the fact that protons bound to fat molecules resonate at a slightly different frequency than water protons, a phenomenon known as chemical shift.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Suppression of signal from flowing blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;In conventional multislice spin-echo imaging, the region outside the imaged volume does not absorb RF energy, and spins from this region are therefore fully relaxed (maximum magnetic moment). If these spins flow into the imaged volume during data acquisition, ie, arterial or venous inflow, they will generate relatively high signal intensity and will also produce phase-shift artifacts. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Flow compensation (gradient moment nulling)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This undesired blood flow artifact can be suppressed by presaturating the nonimaged volume with a 90 degree RF excitation and randomizing the phase of these spins with a large magnetic field gradient, at a small cost in increased imaging time. Spatial presaturation is routinely used in spin-echo thoracic imaging sequences to reduce blood flow artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Suppression of respiratory motion artifact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppression of respiratory motion artifact can be achieved by presaturating the anterior chest wall to reduce its emitted signal. This type of saturation within the imaged slice is used mainly in conjunction with surface phased-array coils. These receiver coils greatly increase the signal-to-noise ratio obtained per unit of imaging time; however, they suffer from nonuniform spatial sensitivity. Thus, signal from protons close to the coil, ie, the chest wall, is received with greater efficiency than signal from protons deep within the thorax. Spatial presaturation can deemphasize the signal from the chest wall and therefore reduce respiratory artifact arising from the chest wall as well. The main limitation of spatial presaturation for this application is that only a linear band of tissue can be suppressed with a single pulse. To suppress signal from the entire chest cage, multiple presaturation pulses must be applied, at a greater cost in imaging time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Suppression of signal from fat",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, chemical-shift fat suppression is commonly used to reduce the high signal intensity of fat-containing tissues. This comes at a modest cost in imaging time. Chemical fat suppression is effective but relies on a high degree of magnetic field homogeneity within the imaged volume: since the difference in resonant frequency of water and fat protons is only 3.5 parts per million, any variation in the magnetic field of this order or larger will cause uneven fat suppression. The problem is exacerbated on lower field strength imaging systems since the fat-selective prepulses have a finite bandwidth that is more likely to overlap the water resonance frequency due to the very narrow difference in resonant frequencies.",
"   </p>",
"   <p>",
"    A common alternative method of fat suppression is known as STIR (Short Tau Inversion Recovery), which exploits the fact that the relaxation time of fat protons is much shorter than water protons. By exciting all tissue within a volume to invert the magnetization (180 degree pulse), followed by a delay chosen when fat protons have no net magnetic moment, followed by a 90 degree pulse and then readout pulses, signal from fat can be suppressed without requiring high field homogeneity. The main disadvantage of this method over chemical fat suppression is that it is slower.",
"   </p>",
"   <p>",
"    Use of fat suppression within the thorax enables tissue characterization when a fat-containing lesion is suspected (either method effective), and facilitates differentiation of fat from contrast enhancement after intravenous contrast administration, where enhancing tissue and nonsuppressed fat may approach equal signal intensity (only CHEM SAT effective).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRACTICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the MR examination, the patient typically lies supine on a sliding table, which is advanced into the bore of the magnet for imaging. Since noise levels can be high during imaging due to vibration of the gradient coils, earplugs or specially designed in-ear audio systems are commonly used. An imaging sequence may be as short as one second or as long as 10 minutes, and the entire exam typically lasts 20 to 45 minutes as multiple imaging sequences are performed in multiple planes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few contraindications to MR imaging exist and no biological effects are associated with conventional MR imaging. Most contraindications are relative precautions, which can be divided into four groups &mdash; implanted devices and foreign bodies, unstable patients, pregnancy, and other [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to scanning, a thorough safety screen of each patient for any implanted, embedded or attached devices or foreign objects is mandatory. Screening should include taking a history for possible intraorbital or intraocular metallic fragments, such as might become lodged during machining. Patients are generally asked to remove jewelry and clothing containing metallic components and change into a gown.",
"   </p>",
"   <p>",
"    Magnetizable materials and electronic devices represent potential hazards to the patient. A separate issue is that implanted devices and foreign bodies may induce image artifacts that impact the diagnostic quality of images.",
"   </p>",
"   <p>",
"    The American Society for Testing and Material International developed the following terminology for labeling of implanted devices [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MR safe &mdash; An item that poses no known hazards in any MR environment.",
"     </li>",
"     <li>",
"      MR conditional &mdash; An item that has been demonstrated to pose no known hazards in a specified MR imaging environment with specified conditions of use.",
"     </li>",
"     <li>",
"      MR unsafe &mdash; An item that is known to pose hazards in all MR environments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since no guideline can cover all devices, when the safety of particular devices is being considered, readers are referred to safety information for specific devices such as that compiled on dedicated Web sites [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/20,21\">",
"     20,21",
"    </a>",
"    ] and, when available, manufacturer's product information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cardiovascular devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association (AHA) scientific statement on safety of magnetic resonance imaging in patients with cardiovascular devices provided recommendations for imaging patients with these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Timing of MR examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of MR imaging after implantation of a cardiovascular device was addressed in the AHA statement. In general, if a device is nonferromagnetic and there are no concerns associated with MR-related heating, MR imaging may be performed immediately after implantation. For some weakly ferromagnetic devices, data and consensus are sufficient to support a recommendation that MR examination can be performed any time after implantation. For other weakly ferromagnetic devices, the writing group recommended weighing the risks and benefits of scanning on an individual basis. In some cases (eg, those with acute indications), there may be clear potential benefit to scanning within days to weeks after device implantation while in other cases when the indication for scanning is not very time sensitive, it may be prudent to defer MR examination until approximately six weeks after implantation (based on the general belief that tissue healing occurring over weeks may aid in device anchoring).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Coronary artery and peripheral vascular stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA statement noted that most coronary artery stents and peripheral vascular stents that have been tested have been labeled as \"MR safe\" and the remainder have been labeled as \"MR conditional\". Tested coronary artery stents (including tested drug-eluting coronary stents) and peripheral stents that are nonferromagnetic (includes all coronary artery stents in use in 2007) can be safely scanned at &le;3T any time after implantation. The timing of MR examination (from days to six weeks after implantation) at &le;3T for patients with peripheral stents that are weakly ferromagnetic should be decided on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Aortic stent grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AHA statement noted that most aortic stent grafts that have been tested have been labeled as \"MR safe\". The Zenith AAA and TAA endovascular grafts (Cook) are now labeled as \"MR conditional\" (which supersedes prior labeling as &ldquo;MR unsafe&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with nonferromagnetic stent grafts may be scanned at &le;3T at any time after implantation. The timing of MR examination at &le;3T for patients with weakly ferromagnetic aortic stent grafts should be decided on a case by case basis. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Timing of MR examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most stent grafts cause minimal artifacts and allow visualization of endostent lumen and evidence of endostent leak. However, severe susceptibility artifacts have been reported with the Zenith AAA endovascular graft, Endologix AAA stent (Endologix) and Lifepath AAA stent (Edwards Lifesciences Corp), so MR is not the modality of choice for evaluation of these stent grafts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Mechanical cardiac valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA statement noted that the majority of prosthetic heart valves and annuloplasty rings have been labeled as \"MR safe\"; the remainder of tested heart valves and rings have been labeled as \"MR conditional\". The presence of a prosthetic heart valve or annuloplasty ring that has been formally evaluated for MR safety should not be considered a contraindication to MR examination at &le;3 T any time after implantation.",
"   </p>",
"   <p>",
"    Sternal wires are generally considered safe for MR scanning (although local artifact will result).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cardiac closure and occluder devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA statement noted that the majority of cardiac closure and occluder devices have been labeled as \"MR safe\"; several tested devices have been labeled as \"MR conditional\". Patients with nonferromagnetic cardiac closure and occluder devices may undergo MR examination any time after implantation. Timing of imaging for patients with weakly ferromagnetic devices at &le;3T should be determined on an individual basis. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Timing of MR examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Inferior vena cava filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA statement noted that most inferior vena cava (IVC) filters that have been tested have been labeled as \"MR safe\"; the remainder of tested IVC filters are classified as \"MR conditional\". Most have been studied at &le;1.5T although many have been studied at 3T. Patients with nonferromagnetic devices may undergo MR examination at any time. It is advised that patients with weakly ferromagnetic devices (eg, Gianturco bird nest IVC filter (Cook), stainless steel Greenfield vena cava filter (Boston Scientific)) wait at least six weeks before undergoing an MR examination, unless there is a strong clinical indication to perform the MR examination sooner. MR examination can be performed after six weeks if clinically indicated as long as there is no reason to suspect that the device is not positioned properly or that it is not firmly in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Embolization coils",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA statement noted that most embolization coils that have been tested have been labeled as \"MR safe\"; the remainder of tested coils has been labeled as \"MR conditional\". Patients with nonferromagnetic cardiac closure and occluder devices may undergo MR examination any time after implantation. Timing of imaging for patients with weakly ferromagnetic devices at &le;3T should be determined on an individual basis. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Timing of MR examination'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Loop recorder (Event monitor)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Reveal Plus ILR has been labeled as \"MR conditional\". Patients with this device can undergo MR examination any time after implantation provided there is no reason to believe the device is not well implanted. Since stored data may be affected, all data should be downloaded before scanning. The patient should we warned that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    may feel the device move since it contains ferromagnetic components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Hemodynamic monitoring and temporary pacing devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The few catheters that contain conducting wires and the few temporary transvenous pacing wires that have been tested have been labeled as \"MR unsafe\".",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with pulmonary artery hemodynamic",
"      <span class=\"nowrap\">",
"       monitoring/thermodilution",
"      </span>",
"      catheters (eg, the Swan-Ganz catheter) and similar catheters should not undergo MR examinations because of the possible risks, unless in vivo testing provides labeling information that permits safe MR imaging. Patients with verified nonferromagnetic pulmonary artery catheters that contain no electrically conductive pathways may undergo MR examination.",
"     </li>",
"     <li>",
"      Patients with retained temporary epicardial pacing wires are believed to be able to undergo MR examination safely.",
"     </li>",
"     <li>",
"      Temporary pacemaker external pulse generators should not be introduced to the MR environment because of potential risks. Scanning of patients with transvenous temporary pacing leads (without the generator) is not recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Permanent pacemakers and implantable cardioverter-defibrillators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks of scanning patients with permanent pacemakers or implantable cardioverter-defibrillators (ICDs) are related to possible movement of the device, programming changes, asynchronous pacing, activation of tachyarrhythmia therapies, inhibition of pacing output, and induced currents in lead wires leading to heating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiac stimulation.",
"   </p>",
"   <p>",
"    However, a number of series have reported on the relative safety of scanning patients with pacemakers or ICDs under carefully supervised conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/24\">",
"     24",
"    </a>",
"    ]. Despite these reports, the presence of a pacemaker or ICD is still generally considered a strong relative contraindication to routine MR examination [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MR imaging in patients with permanent pacemakers or ICD should be undertaken only if no alternative diagnostic test is available and the potential benefit to the patient clearly outweighs the potential risks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/24\">",
"     24",
"    </a>",
"    ]. If scanning is performed, it should occur only at highly experienced centers with expertise in MR imaging and electrophysiology, with a formal quality control program to track adverse events. Written informed consent should specifically list risks, including (1)",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    dysfunction, (2)",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    damage, (3) arrhythmia, and (4) death. A physician with",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    expertise should be present during scanning and a defibrillator with crash cart should be available. An expert in MR physics and safety should be involved with the scan to optimize the protocol to minimize risk. The",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    should be interrogated before and after the procedure. Detailed recommendations for the performance of MR examinations in this setting are available [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major device manufacturers have developed some MRI compatible systems. These include the St. Jude",
"    <strong>",
"    </strong>",
"    Medical Accent MRI",
"    <sup>",
"     TM",
"    </sup>",
"    pacemaker, the BIOTRONIK Evia ProMRI&reg; pacing system, and the Medtronic Advisa, Ensura, and EnRhytm DR MRI",
"    <sup>",
"     TM",
"    </sup>",
"    SureScan&reg; pacing systems which are commercially available in Europe. The Revo MRI",
"    <sup>",
"     TM",
"    </sup>",
"    SureScan&reg; pacing system is available in Europe and the United States.",
"   </p>",
"   <p>",
"    MR examination should not be performed in patients with pacemakers or ICDs with known lead fractures since fractured leads may pose a particularly high risk of thermal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Retained transvenous pacemaker and defibrillator leads",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 AHA writing group noted the lack of safety data for retained leads and recommended that patients with retained leads be approached similarly to those with pacemakers or ICDs. MR examination should not be performed in patients with known retained fractured transvenous leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Hemodynamic support devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although formal evaluation of intra-aortic balloon pump and ventricular assist devices for MR safety has not been performed, the 2007 AHA writing group consensus was that these devices should be considered absolute contraindications to MR examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Other implanted electronic devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve stimulators, cochlear implants, and other implanted electronic devices also may be affected by MRI and are considered unsafe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with an implanted vagal nerve stimulator, a brain MRI performed at &lt;2 Tesla, with a send and receive head coil and the stimulator turned off, appears to be safe under guidelines published by the manufacturer. Other MRI studies are not known to be safe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link&amp;anchor=H12#H12\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Aneurysm clips",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate safety screening of patients with aneurysm clips requires specific information about the clip, particularly its material. The hazard of a ferromagnetic aneurysm clip primarily reflects the possibility of deflection sufficient to injure vital structures with potentially dire consequences. Ferromagnetic intracranial aneurysm clips are an absolute contraindication to the use of MR procedures. On the other hand, aneurysm clips classified as nonferromagnetic or weakly ferromagnetic are safe for patients undergoing MR procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other foreign materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most metallic biomaterials are now nonferrous and nonmagnetizable, any metallic device within or connected to the patient needs to be evaluated for safety [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The presence of dental materials such as alloys, wires, splints, and prostheses does not appear to generally pose a risk to the patient, although these materials may cause artifacts. [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/29\">",
"     29",
"    </a>",
"    ]. On the other hand, cutaneous burns can result from skin contact with metal objects, including neurosurgical halo pins and pulse oximetry probes which may result from induction or resonant coupling with associated generation of heat [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/30-35\">",
"     30-35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Transdermal patches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneously applied drug-eluting adhesive patches that contain aluminum or other metals in their non-adhesive backing should NOT be worn during MRI due to the risk of causing burns [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/31,36\">",
"     31,36",
"    </a>",
"    ]. Examples of metal-containing transdermal patches include certain patches containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    , nicotine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    , testosterone, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    . In March 2009, the FDA issued a Public Health Advisory after learning that a warning was missing on some metal-containing medicated patches [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/37\">",
"     37",
"    </a>",
"    ]. The FDA recommended that healthcare professionals referring patients for an MRI scan identify those patients who are wearing a patch and advise these patients about procedures for removing and disposing of the patch before the MRI scan and replacing the patch after the scan. MRI facilities should follow safe practice recommendations in screening patients prior to MRI to ensure that they are not wearing any metallic drug delivery patches or other unnecessary metallic objects such as jewelry [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Unstable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of difficult access to a patient within the magnet and because most resuscitation equipment cannot be brought into the scanning room, an unstable patient probably should not undergo MR imaging unless there is an urgent clinical indication without another acceptable imaging alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks posed to the developing fetus by MRI are unknown. These risks, if any, are probably low and use of MRI may help avoid ionizing radiation associated with other imaging modalities. Gadolinium-based contrast agents cross the placenta and are not recommended for use in pregnant patients unless the potential benefit justifies the potential risk to the fetus. MRI is indicated for use in pregnant women if the potential benefit outweighs the potential risk. It is prudent, however, to inform pregnant patients that, although there have been no demonstrated untoward effects of MRI in pregnancy, its safety remains unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?5/35/5689/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     MR contrast agents and renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major route of MR contrast excretion is renal. However, unlike iodinated contrast media MR contrast agents have few side effects, and rarely cause anaphylactoid reactions. As a result, MR contrast agents are generally safer than iodinated contrast agents in patients who are unstable or have impaired renal function or a prior history of anaphylactoid reaction to iodinated contrast agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, two potential concerns with MR gadolinium-based contrast agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with moderate to severe chronic kidney disease, contrast nephropathy can occur, although the risk is less well documented than with iodinated contrast media. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link&amp;anchor=H23#H23\">",
"       \"Prevention of contrast-induced nephropathy\", section on 'Contrast-enhanced MRI as an alternative'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among patients with moderate to severe kidney disease, particularly dialysis patients, as well as patients with hepatorenal syndrome and patients in the perioperative liver transplant period, gadolinium has been associated with the potentially severe, and sometimes fatal, syndrome of nephrogenic systemic fibrosis (NSF). Therefore, gadolinium-containing intravenous contrast agents should be avoided in such patients, whenever possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"       \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other problems occur in selected cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small fraction of patients experience claustrophobia when asked to lie within an MR scanner. For some, this may be severe enough to require sedation. Various remedies, including MR compatible music and video systems, are commercially available. A large number of so-called \"open\" MRI systems have been installed to cater to patients who are claustrophobic or are too large for a cylindrical bore magnet.",
"     </li>",
"     <li>",
"      An agitated patient or one who cannot hold still within the magnet is a poor candidate for MR imaging unless sufficiently sedated.",
"     </li>",
"     <li>",
"      Some obese or large patients may not be able to fit into the bore of the magnet. Some of these patients can be accommodated by an open MR imaging system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20514173\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI is an imaging technology using nonionizing radiofrequency radiation inside a strong magnetic field to detect the location and local chemical environment of protons in water molecules. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'MR physics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'MR imaging technology and pulse sequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unlike computed tomography, which detects only differences in electron density, the tissue contrast that can be achieved&nbsp;with MRI is extremely flexible and orders of magnitude greater.",
"     </li>",
"     <li>",
"      Limitations of MRI include hazards posed by certain metallic devices inside patients, for which extensive safety references are available, and claustrophobia in some patients.&nbsp;So-called open MRI scanners and short-bore conventional scanners can accommodate most claustrophobic patients.",
"     </li>",
"     <li>",
"      As with CT,&nbsp;intravenous injection of contrast agents&nbsp;is often used to improve contrast between pathologic and normal tissues or to perform angiography. Most MRI contrast agents now carry a \"black box\" warning regarding the risk of inducing nephrogenic systemic fibrosis (NSF) in patients with renal failure. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'MR contrast agents and renal failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/1\">",
"      Bittner RC, Felix R. Magnetic resonance (MR) imaging of the chest: state-of-the-art. Eur Respir J 1998; 11:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/2\">",
"      Andrew ER. Nuclear magnetic resonance and the brain. Brain Topogr 1992; 5:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/3\">",
"      Lauterbur PC. Progress in n.m.r. zeugmatography imaging. Philos Trans R Soc Lond B Biol Sci 1980; 289:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/4\">",
"      Damadian R. Field focusing n.m.r. (FONAR) and the formation of chemical images in man. Philos Trans R Soc Lond B Biol Sci 1980; 289:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/5\">",
"      Lai CM, Lauterbur PC. True three-dimensional image reconstruction by nuclear magnetic resonance zeugmatography. Phys Med Biol 1981; 26:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/6\">",
"      Seynaeve PC, Broos JI. [The history of tomography]. J Belge Radiol 1995; 78:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/7\">",
"      Andrew ER. The Wellcome Foundation lecture, 1981. Nuclear magnetic resonance imaging in medicine: physical principles. Proc R Soc Lond B Biol Sci 1985; 225:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/8\">",
"      Garroway AN. Solid state NMR, MRI and Sir Peter Mansfield: (1) from broad lines to narrow and back again; and (2) a highly tenuous link to landmine detection. MAGMA 1999; 9:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/9\">",
"      Mustarelli P, Rudnicki M, Savini A, et al. Synthesis of magnetic gradients for NMR tomography. Magn Reson Imaging 1990; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/10\">",
"      Vogt FM, Goyen M, Debatin JF. MR angiography of the chest. Radiol Clin North Am 2003; 41:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/11\">",
"      Finn JP, Baskaran V, Carr JC, et al. Thorax: low-dose contrast-enhanced three-dimensional MR angiography with subsecond temporal resolution--initial results. Radiology 2002; 224:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/12\">",
"      Riederer SJ, Bernstein MA, Breen JF, et al. Three-dimensional contrast-enhanced MR angiography with real-time fluoroscopic triggering: design specifications and technical reliability in 330 patient studies. Radiology 2000; 215:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/13\">",
"      Holmqvist C, St&aring;hlberg F, Laurin S. Contrast-enhanced thoracic 3D-MR angiography in infants and children. Acta Radiol 2001; 42:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/14\">",
"      Okuda S, Kikinis R, Geva T, et al. 3D-shaded surface rendering of gadolinium-enhanced MR angiography in congenital heart disease. Pediatr Radiol 2000; 30:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/15\">",
"      White CS. MR imaging of thoracic veins. Magn Reson Imaging Clin N Am 2000; 8:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/16\">",
"      Cohen MS, Weisskoff RM. Ultra-fast imaging. Magn Reson Imaging 1991; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/17\">",
"      Kanal E, Borgstede JP, Barkovich AJ, et al. American College of Radiology White Paper on MR Safety: 2004 update and revisions. AJR Am J Roentgenol 2004; 182:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/18\">",
"      Marcu CB, Beek AM, van Rossum AC. Clinical applications of cardiovascular magnetic resonance imaging. CMAJ 2006; 175:911.",
"     </a>",
"    </li>",
"    <li>",
"     American Society for Testing and Materials (ASTM) International. ASTM F2503-05: Standard Practice for Marking Medical Devices and Other Itmes for Safety in the Magnetic Resonance Environment. ASTM International ,West Conshohocken, PA. 2005. Available at: file://www.astm.org.",
"    </li>",
"    <li>",
"     MRI safety. Institute for Magnetic Resonance Safety, Education, and Research Web site. file://222.MRIsafety.com (Accessed on February 06, 2008).",
"    </li>",
"    <li>",
"     MR safety. 2006. http//www.acr.org/SecondaryMainMenuCategories/quality_safety/MRSafety.aspx (Accessed on February 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/22\">",
"      Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: an American Heart Association scientific statement from the Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology, and the Council on Cardiovascular Radiology and Intervention: endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation 2007; 116:2878.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cookmedical.com/ai/productMri.do (Accessed on August 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/24\">",
"      Zikria JF, Machnicki S, Rhim E, et al. MRI of patients with cardiac pacemakers: a review of the medical literature. AJR Am J Roentgenol 2011; 196:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/25\">",
"      Roguin A, Schwitter J, Vahlhaus C, et al. Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. Europace 2008; 10:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/26\">",
"      Sharan A, Rezai AR, Nyenhuis JA, et al. MR safety in patients with implanted deep brain stimulation systems (DBS). Acta Neurochir Suppl 2003; 87:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/27\">",
"      Romner B, Olsson M, Ljunggren B, et al. Magnetic resonance imaging and aneurysm clips. Magnetic properties and image artifacts. J Neurosurg 1989; 70:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/28\">",
"      Shellock FG. MR imaging of metallic implants and materials: a compilation of the literature. AJR Am J Roentgenol 1988; 151:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/29\">",
"      Hub&aacute;lkov&aacute; H, Hora K, Seidl Z, Kr&aacute;sensk&yacute; J. Dental materials and magnetic resonance imaging. Eur J Prosthodont Restor Dent 2002; 10:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/30\">",
"      Kim LJ, Sonntag VK, Hott JT, et al. Scalp burns from halo pins following magnetic resonance imaging. Case illustration. J Neurosurg 2003; 99:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/31\">",
"      Karch AM. Don't get burnt by the MRI: transdermal patches can be a hazard to patients. Am J Nurs 2004; 104:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/32\">",
"      Dempsey MF, Condon B. Thermal injuries associated with MRI. Clin Radiol 2001; 56:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/33\">",
"      Dempsey MF, Condon B, Hadley DM. Investigation of the factors responsible for burns during MRI. J Magn Reson Imaging 2001; 13:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/34\">",
"      Nakamura T, Fukuda K, Hayakawa K, et al. Mechanism of burn injury during magnetic resonance imaging (MRI)--simple loops can induce heat injury. Front Med Biol Eng 2001; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/35\">",
"      Severinghaus JW, Kelleher JF. Recent developments in pulse oximetry. Anesthesiology 1992; 76:1018.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for screening patients for MR procedures and individuals for the MR environment, institute for magnetic resonance safety, education, and research, 2009. file://www.imrser.org/PaperPDFRecord.asp?WebRecID=102&amp;PgName=Guidelines&amp;WebRecID=&amp;sb_SummaryTitle=&amp;).",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm111313.htm (Accessed on August 06, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/35/5689/abstract/38\">",
"      Shellock FG, Kanal E. Policies, guidelines, and recommendations for MR imaging safety and patient management. SMRI Safety Committee. J Magn Reson Imaging 1991; 1:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5309 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5689=[""].join("\n");
var outline_f5_35_5689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20514173\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MR PHYSICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MR IMAGING TECHNOLOGY AND PULSE SEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Magnet and coil design",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulse sequences",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Spin echo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Gradient echo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Other sequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MAGNETIC RESONANCE CONTRAST AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MOTION COMPENSATION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiac gating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Respiratory compensation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Flow compensation (gradient moment nulling)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPATIAL AND CHEMICAL PRESATURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Suppression of signal from flowing blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Suppression of respiratory motion artifact",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Suppression of signal from fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRACTICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cardiovascular devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Timing of MR examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Coronary artery and peripheral vascular stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Aortic stent grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Mechanical cardiac valves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cardiac closure and occluder devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Inferior vena cava filters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Embolization coils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Loop recorder (Event monitor)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Hemodynamic monitoring and temporary pacing devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Permanent pacemakers and implantable cardioverter-defibrillators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Retained transvenous pacemaker and defibrillator leads",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Hemodynamic support devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Other implanted electronic devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Aneurysm clips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other foreign materials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Transdermal patches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Unstable patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      MR contrast agents and renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20514173\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5309\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5309|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/10/11437\" title=\"figure 1\">",
"      Macroscopic magnetic moment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/45/38620\" title=\"figure 2A\">",
"      Longitudinal relaxation in MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/62/3053\" title=\"figure 2B\">",
"      Longitudinal recovery in MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/37/18013\" title=\"figure 3A\">",
"      Transverse relaxation in MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/32/31244\" title=\"figure 3B\">",
"      Transverse recovery in MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/3/13375\" title=\"figure 4\">",
"      Imaging magnet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31305?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3910?source=related_link\">",
"      Magnetic resonance imaging of the thorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_35_5690="Superficial spreading melanoma 4";
var content_f5_35_5690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71893%7EDERM%2F82173%7EDERM%2F75881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71893%7EDERM%2F82173%7EDERM%2F75881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion is asymmetric, and presents border irregularity, color variegation, and a nodular component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion is asymmetric, has irregular borders, and more than three colors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Destruction of the nail bed by the tumor is present in this patient with subungual melanoma involving the toe. Note the presence of pigment involving the periungual skin (Hutchinson's sign).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5690=[""].join("\n");
var outline_f5_35_5690=null;
var title_f5_35_5691="Secondary causes of short QT interval on ECG";
var content_f5_35_5691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Secondary causes of short QT interval on ECG",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Hyperkalemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effect of catecholamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activation of ATP-sensitive potassium current",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Activation of acetylcholine-sensitive potassium current",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Effects of drugs like digitalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myocardial ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased vagal tone",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5691=[""].join("\n");
var outline_f5_35_5691=null;
var title_f5_35_5692="Common symptoms IEI";
var content_f5_35_5692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57038&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common symptoms in patients with idiopathic environmental intolerance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Organ system",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head, eye, ear, nose, and throat",
"       </td>",
"       <td>",
"        Eye burning or pruritis, tinnitus, buzzing, sudden deafness, visual impairment, rhinorrhea, nasal obstruction, odor sensitivity, glossodynia, pharyngeal irritation, dysphonia, hoarseness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary",
"       </td>",
"       <td>",
"        Dyspnea, cough, chest pain, shortness of breath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular",
"       </td>",
"       <td>",
"        Palpitations, irregular heartbeat, tachycardia, chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td>",
"        Stomach pain, gastritis, indigestion, dyspepsia, anorexia, constipation, cramps, nausea, vomiting, diarrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitourinary",
"       </td>",
"       <td>",
"        Dysmenorrhea, vaginitis, dysuria, urinary frequency, urinary retention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Musculoskeletal",
"       </td>",
"       <td>",
"        Myalgia, weakness, muscle tension, arthralgia, skin irritation, pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endocrine",
"       </td>",
"       <td>",
"        Hot flashes, chills, polydipsia, hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphatic",
"       </td>",
"       <td>",
"        Change in size of lymph nodes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatologic",
"       </td>",
"       <td>",
"        Diaphoresis, pruritis, burning, rash, alopecia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurologic",
"       </td>",
"       <td>",
"        Headaches, paresthesias, paralysis, seizures, convulsions, dizziness, light headedness, weakness, pain syndromes, tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric",
"       </td>",
"       <td>",
"        Fatigue, drowsiness, irritability, hyperactivity, insomnia, mental slowing or confusion, inattention, poor concentration, memory deficits, depression, anxiety, irritability, anhedonia, mood lability, crying spells",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5692=[""].join("\n");
var outline_f5_35_5692=null;
var title_f5_35_5693="Amyloidosis prognostic staging systems";
var content_f5_35_5693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prognostic staging systems for amyloidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Prognostic model",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Risk groups",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Survival in patients not undergoing stem cell transplantation",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Survival in patients undergoing stem cell transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Median in months",
"       </td>",
"       <td class=\"subtitle2\">",
"        Five-year survival rate (percent)*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Median in months",
"       </td>",
"       <td class=\"subtitle2\">",
"        Four-year survival rate (percent)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Mayo stage",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        Cardiac troponin &lt;0.035 mcg/L and NT-proBNP &lt;332 ng/L",
"       </td>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Not reached at 40 months",
"       </td>",
"       <td>",
"        85",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        Any one factor high",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Not reached at 40 months",
"       </td>",
"       <td>",
"        75",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        Cardiac troponin &ge;0.035 mcg/L and NT-proBNP &ge;332 ng/L",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        25",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Revised Mayo stage",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        NT-pro-BNP &lt;1800 ng/L, cardiac troponin T &lt;0.025 mcg/L, and difference between involved and uninvolved serum free light chains &lt;18 mg/dL",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Not reached",
"       </td>",
"       <td>",
"        87",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        Any one factor high",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        Any two factors high",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        NT-pro-BNP &ge;1800 ng/L, cardiac troponin T &ge;0.025 mcg/L, and difference between involved and uninvolved serum free light chains &ge;18 mg/dL",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Estimated from published survival curve if not reported.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Survival rate at 40 months.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22:3751.",
"      </li>",
"      <li>",
"       Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104:1881.",
"      </li>",
"      <li>",
"       Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012; 30:989.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5693=[""].join("\n");
var outline_f5_35_5693=null;
var title_f5_35_5694="Decision tree for thrombolysis";
var content_f5_35_5694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decision tree for thrombolysis in the elderly (example data for decision analysis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 401px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Created with data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5694=[""].join("\n");
var outline_f5_35_5694=null;
var title_f5_35_5695="Rhomboid flap closure for pilonidal disease excision";
var content_f5_35_5695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F87175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F87175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Rhomboid flap closure for pilonidal disease excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intergluteral pilonidal disease is completely excised and closed with a rhomboid (Limberg) flap. Figure A depicts the incisions and Figure B depicts the rotation of the flap.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_35_5695=[""].join("\n");
var outline_f5_35_5695=null;
